var title_f29_25_30096="Severe dry eye 2";
var content_f29_25_30096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dry eye disease with loss of luster of the conjunctival and corneal surface associated with breakdown of the normal ocular epithelial surfaces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30096=[""].join("\n");
var outline_f29_25_30096=null;
var title_f29_25_30097="Pneumobelt";
var content_f29_25_30097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumobelt",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 240px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pneumobelt is shown connected to the Thompson Bantam positive pressure ventilation. The ventilator intermittently inflates a rubber bladder contained within the corset.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30097=[""].join("\n");
var outline_f29_25_30097=null;
var title_f29_25_30098="Primary megaureter";
var content_f29_25_30098=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary megaureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 608px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram of primary megaureter that demonstrates the location of a functional or anatomical abnormality at the ureterovesical junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin LS, Kogan BA. Handbook of Pediatric Urology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30098=[""].join("\n");
var outline_f29_25_30098=null;
var title_f29_25_30099="Ganirelix: Drug information";
var content_f29_25_30099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganirelix: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/13/5332?source=see_link\">",
"    see \"Ganirelix: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Orgalutran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin Releasing Hormone Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to controlled ovarian hyperstimulation: SubQ: 250 mcg/day during the mid-to-late phase after initiating follicle-stimulating hormone on day 2 or 3 of cycle. Treatment should be continued daily until the day of chorionic gonadotropin administration.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as acetate: 250 mcg/0.5 mL (1 mL) [contains natural rubber/natural latex in packaging]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6265422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer SubQ in abdomen (around upper navel) or upper thigh; rotate injection site.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3122008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Antagon former U.S. brand name for ganirelix, but also the brand name for ranitidine in Brazil",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ovarian hyperstimulation syndrome (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (1%), nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pelvic pain (5%), vaginal bleeding (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ganirelix or any component of the formulation; hypersensitivity to gonadotropin-releasing hormone (GnRH) or any other GnRH analog; known or suspected pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions, including anaphylactoid reactions, have been reported; may occur with the first dose; risk may be increased in patients with other allergic conditions; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Exclude pregnancy before beginning treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: The packaging contains natural rubber latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced specialists: Should only be prescribed by fertility specialists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal resorption occurred in pregnant rats and rabbits. These effects are results of hormonal alterations and could result in fetal loss in humans. The drug should not be used in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F177293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if ganirelix is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ganirelix Acetate Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg/0.5 mL (0.5 mL): $144.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F177264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ultrasound to assess follicle size",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Orgalutran (AE, AR, AT, AU, BE, BG, BH, BR, CH, CN, CO, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IQ, IR, IT, JO, KW, LB, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PK, PL, PT, QA, RU, SA, SE, SG, SK, SY, TH, TR, TW, UY, VE, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks the gonadotropin-release hormone receptors on the pituitary gonadotroph and transduction pathway. This suppresses gonadotropin secretion and luteinizing hormone secretion preventing ovulation until the follicles are of adequate size.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &lt;48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:  Mean V",
"     <sub>",
"      d",
"     </sub>",
"     : Single dose: 43.7 L; Multiple dosing: 76.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 81.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to two primary metabolites (1-4 and 1-6 peptide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: 91.1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Single dose: 12.8 hours; Multiple dosing: 16.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (75%) within 288 hours; urine (22%) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8666 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30099=[""].join("\n");
var outline_f29_25_30099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177286\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177306\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177289\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177290\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896340\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896341\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177266\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177252\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6265422\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177267\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3122008\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177304\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177270\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177256\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299388\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177260\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177262\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177293\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265802\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422232\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177264\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177272\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177255\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177269\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/13/5332?source=related_link\">",
"      Ganirelix: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_25_30100="Management of zipper injuries";
var content_f29_25_30100=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of zipper injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30100/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30100/contributors\">",
"     Joan Bothner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30100/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30100/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30100/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30100/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/25/30100/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zipper entrapment of the penis is an uncommon injury in prepubertal boys. These injuries typically involve the foreskin or redundant penile skin and may occur during the zipping or unzipping process [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/1\">",
"     1",
"    </a>",
"    ]. Localized edema, superficial tissue abrasions, bruising, and pain are the most common complications of zipper injuries; skin loss or necrosis, is unusual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zipper entrapment injuries occur infrequently. In one case series from a pediatric emergency department, one zipper entrapment injury occurred per 4000 new emergency department attendees [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/2\">",
"     2",
"    </a>",
"    ]. In this series of 30 boys between the ages of 2 and 12 years of age, 60 percent of the affected boys were wearing underwear at the time of the injury. Most of the injuries were self-inflicted (84 percent) and occurred as the zipper was being zipped up as opposed to down (92 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311554\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, the uncircumcised foreskin is entrapped in the zipper (",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"UTD.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/3\">",
"     3",
"    </a>",
"    ]. Occasionally redundant tissue on the ventral side of the circumcised penis is involved.",
"   </p>",
"   <p>",
"    A zipper is composed of interlocking dentitions that are aligned by a fastener consisting of an inner faceplate, outer faceplate and median bar (",
"    <a class=\"graphic graphic_picture graphicRef58314 \" href=\"UTD.htm?2/61/3025\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/3\">",
"     3",
"    </a>",
"    ]. The fastener and cloth hold the zipped dentitions together. If either the cloth or fastener is disrupted, the zipped dentitions fall apart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311562\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should attempt removal of entrapped penile tissue as soon as possible after the zipper injury. With time, swelling and edema of the entrapped tissue makes successful management more difficult. Penile entrapment that involves the urethra or falls attempts using the procedures described below warrants prompt referral to or consultation with an urologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311570\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child and caregiver should receive an explanation of the procedure. Reassurance and a gentle approach to the injury help to gain patient cooperation and facilitate successful management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311440\">",
"    <span class=\"h2\">",
"     Sedation and pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to analgesia and anesthesia is essential in the management of boys with zipper injuries. Involvement of a trained child life specialist is advised to provide nonpharmacologic interventions to decrease the pain and anxiety caused by the procedure. Sedation, with appropriate monitoring and personnel, may be warranted in uncooperative patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9810261\">",
"    <span class=\"h3\">",
"     Local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical anesthesia with liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (eg, LMX&reg;) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32150?source=see_link\">",
"     lidocaine-prilocaine",
"    </a>",
"    cream (eg, EMLA&reg;) has been shown to provide effective anesthesia for pediatric urologic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. They may also be effective for alleviation of zipper entrapment although such use has not been studied. Liposomal lidocaine is preferable because it does not require occlusion and is effective after only 30 minutes of application. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H21#H21\">",
"     \"Topical anesthetics in children\", section on 'Liposomal lidocaine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link&amp;anchor=H11#H11\">",
"     \"Topical anesthetics in children\", section on 'EMLA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local infiltration with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    can be used before attempting zipper removal or disengagement of the entrapped penile skin if immediate management is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311462\">",
"    <span class=\"h3\">",
"     Dorsal penile block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dorsal penile nerve block, more invasive and with potential for greater morbidity, should be reserved for entrapments involving a significant amount of tissue or skin. Dorsal penile nerve block is performed as follows (",
"    <a class=\"graphic graphic_figure graphicRef79052 \" href=\"UTD.htm?31/12/31938\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cleanse the base of the penis with povidone-iodine solution.",
"     </li>",
"     <li>",
"      Prepare a syringe with 1 to 5 cc of 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or 0.25 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      without epinephrine. The maximum dose of 1 percent lidocaine is 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mL/kg);",
"      </span>",
"      the maximum dose of 0.25 percent bupivacaine is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.8",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"UTD.htm?25/56/26509\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Insert the needle at the junction of the base of the penis and the suprapubic skin at the 10 o'clock position to a depth of 3 to 5 mm. A \"pop\" is usually felt as the needle pierces Buck fascia.",
"     </li>",
"     <li>",
"      Aspirate to ensure that the needle is not in a blood vessel.",
"     </li>",
"     <li>",
"      Infiltrate the area with one-half of the anesthetic dose.",
"     </li>",
"     <li>",
"      Repeat this process at the 2 o'clock position.",
"     </li>",
"     <li>",
"      Full anesthetic effect occurs after five minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications of dorsal penile nerve block are uncommon. The most frequent complication is bruising. Formation of a hematoma occurs occasionally. Compression or vasospasm of the arterial supply may occur with large volumes of anesthesia or if epinephrine is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311784\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following materials should be assembled:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiseptic solution (eg, povidone-iodine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Topical anesthetic (eg, liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      [LMX&reg;])",
"     </li>",
"     <li>",
"      Syringe with small gauge needle (eg, 27 gauge) with 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or 0.25 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      if local anesthetic infiltration or dorsal penile block is anticipated",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       Mineral oil",
"      </a>",
"     </li>",
"     <li>",
"      Wire cutters, bone cutters, or a mini hacksaw",
"     </li>",
"     <li>",
"      Flathead screwdriver",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2311578\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of zipper injuries is based upon observational studies, primarily case reports and series. [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/2,3,7-12\">",
"     2,3,7-12",
"    </a>",
"    ] The technique for managing zipper injuries depends upon the site of entrapment within the zipper. The following techniques work for plastic and metal zippers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Entrapment of penile skin between the zipper teeth without fastener involvement",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef58314 \" href=\"UTD.htm?2/61/3025\">",
"       picture 1",
"      </a>",
"      ) &ndash; Cut the cloth of the zipper using scissors, which will result in separation of the zipper teeth (",
"      <a class=\"graphic graphic_figure graphicRef61349 \" href=\"UTD.htm?42/27/43442\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/7\">",
"       7",
"      </a>",
"      ]. Local anesthesia or sedation is not typically necessary for this procedure.",
"     </li>",
"     <li>",
"      <strong>",
"       Entrapment of penile skin in the zipper fastener",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef58314 \" href=\"UTD.htm?2/61/3025\">",
"       picture 1",
"      </a>",
"      ) &ndash; The tissue is more difficult to release in patients in whom the penile tissue is entrapped within the zipper fastener. Sedation may be necessary to complete procedures to perform these techniques in anxious or younger children or in patients with a large amount of tissue entrapment; local anesthesia usually is adequate for older children. (See",
"      <a class=\"local\" href=\"#H2311440\">",
"       'Sedation and pain control'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The following methods have been described. The clinician should attempt the least painful and traumatic technique first:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Apply",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      to the affected tissue for 10 to 15 minutes followed by gentle traction to free the penile tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/8\">",
"       8",
"      </a>",
"      ]. The mineral oil technique is simple, nonthreatening, and typically avoids the need for sedation and additional tissue trauma. Anecdotal experience suggests that mild liquid soap (eg, dish washing liquid) may provide sufficient lubrication if mineral oil is not available.",
"     </li>",
"     <li>",
"      Cut the median bar of the fastener (",
"      <a class=\"graphic graphic_picture graphicRef58314 \" href=\"UTD.htm?2/61/3025\">",
"       picture 1",
"      </a>",
"      ) using wire cutters, bone cutters, or a mini hacksaw (",
"      <a class=\"graphic graphic_picture graphicRef63117 \" href=\"UTD.htm?33/42/34465\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef66997 \" href=\"UTD.htm?8/6/8291\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/2,9-11\">",
"       2,9-11",
"      </a>",
"      ]. This allows the mechanism to fall apart and leads to release of the entrapped tissue.",
"     </li>",
"     <li>",
"      Place the thin blade of a flathead screwdriver between the faceplates on the side of the fastener in which the penile tissue is",
"      <strong>",
"       not",
"      </strong>",
"      entrapped (",
"      <a class=\"graphic graphic_picture graphicRef80520 \" href=\"UTD.htm?41/18/42273\">",
"       picture 3",
"      </a>",
"      ). The blade is then rotated toward the median bar to widen the gap between the faceplates and release the tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30100/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After achieving local anesthesia, unzip the zipper back over the entrapped skin or apply lateral traction to the zipper teeth to pull the zipped portion of the zipper apart. Both of these techniques may increase the trauma by repeating the injury to the affected area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the penile tissue remains trapped despite use of these techniques, then prompt consultation with an urologist is warranted for consideration of local excision of entrapped tissue or circumcision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9810276\">",
"    <span class=\"h1\">",
"     AFTERCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penile tissue is frequently swollen and bruised after a zipper injury. Superficial abrasions may also occur. The urethra should be carefully inspected for potential injury.",
"   </p>",
"   <p>",
"    The caregiver should be informed that pain with urination may occur for one to two days after a zipper injury. Dysuria can be moderated by applying triple antibiotic ointment to any skin wounds and by allowing the patient to void while sitting in a tub of warm water. &nbsp;",
"   </p>",
"   <p>",
"    The caregiver should be advised to seek medical attention if the patient is unable to void or has hematuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9810293\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With most zipper injuries the uncircumcised foreskin is entrapped in the zipper. (See",
"      <a class=\"local\" href=\"#H2311554\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A zipper is composed of interlocking dentitions that are aligned by a fastener consisting of an inner faceplate, outer faceplate and median bar (",
"      <a class=\"graphic graphic_picture graphicRef58314 \" href=\"UTD.htm?2/61/3025\">",
"       picture 1",
"      </a>",
"      ). If the fastener or cloth of the zipper is disrupted, the edges will fall apart. (See",
"      <a class=\"local\" href=\"#H2311554\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should attempt removal of entrapped penile tissue as soon as possible after the zipper injury. (See",
"      <a class=\"local\" href=\"#H2311562\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attention to analgesia and anesthesia is essential in the management of boys with zipper injuries. Involvement of a trained child life specialist is advised to provide nonpharmacologic interventions to decrease the pain and anxiety caused by the procedure in addition to any pharmacologic interventions. (See",
"      <a class=\"local\" href=\"#H2311440\">",
"       'Sedation and pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the penile tissue is entrapped between the zipper dentitions without involvement of the fastener (",
"      <a class=\"graphic graphic_picture graphicRef58314 \" href=\"UTD.htm?2/61/3025\">",
"       picture 1",
"      </a>",
"      ), then the clinician may free the tissue by cutting the cloth that holds the zipper (",
"      <a class=\"graphic graphic_figure graphicRef61349 \" href=\"UTD.htm?42/27/43442\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2311578\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the penile tissue is entrapped in the zipper and zipper fastener, then several possible methods may be used. The clinician should attempt the least painful and traumatic technique first. (See",
"      <a class=\"local\" href=\"#H2311578\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the penile tissue remains trapped despite use of these techniques, then prompt consultation with an urologist is warranted for consideration of local excision of entrapped tissue or circumcision. (See",
"      <a class=\"local\" href=\"#H2311578\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/1\">",
"      Yip A, Ng SK, Wong WC, et al. Injury to the prepuce. Br J Urol 1989; 63:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/2\">",
"      Wyatt JP, Scobie WG. The management of penile zip entrapment in children. Injury 1994; 25:59.",
"     </a>",
"    </li>",
"    <li>",
"     Fein JA, Zderic SA. Management of zipper injuries. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA, USA 2008. p.908.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/4\">",
"      Taddio A, Stevens B, Craig K, et al. Efficacy and safety of lidocaine-prilocaine cream for pain during circumcision. N Engl J Med 1997; 336:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/5\">",
"      Lander J, Brady-Fryer B, Metcalfe JB, et al. Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. JAMA 1997; 278:2157.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis LS, Stephan M. Local and Regional Anesthesia. In: Textbook of Pediatric Emergency Procedures, Henretig FM, King C.  (Eds), Williams &amp; Wilkins, Baltimore 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/7\">",
"      Oosterlinck W. Unbloody management of penile zipper injury. Eur Urol 1981; 7:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/8\">",
"      Kanegaye JT, Schonfeld N. Penile zipper entrapment: a simple and less threatening approach using mineral oil. Pediatr Emerg Care 1993; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/9\">",
"      Flowerdew R, Fishman IJ, Churchill BM. Management of penile zipper injury. J Urol 1977; 117:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/10\">",
"      Nolan JF, Stillwell TJ, Sands JP Jr. Acute management of the zipper-entrapped penis. J Emerg Med 1990; 8:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/11\">",
"      Strait RT. A novel method for removal of penile zipper entrapment. Pediatr Emerg Care 1999; 15:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30100/abstract/12\">",
"      Raveenthiran V. Releasing of zipper-entrapped foreskin: a novel nonsurgical technique. Pediatr Emerg Care 2007; 23:463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6326 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30100=[""].join("\n");
var outline_f29_25_30100=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9810293\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311554\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311562\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311570\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2311440\">",
"      Sedation and pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9810261\">",
"      - Local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2311462\">",
"      - Dorsal penile block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2311784\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2311578\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9810276\">",
"      AFTERCARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9810293\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6326|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19462\" title=\"figure 1\">",
"      Penis anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/12/31938\" title=\"figure 2\">",
"      Dorsal penile block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/27/43442\" title=\"figure 3\">",
"      Zipper entrapment release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/6/8291\" title=\"figure 4\">",
"      Zipper fastener release",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6326|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/61/3025\" title=\"picture 1\">",
"      Zipper anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/42/34465\" title=\"picture 2\">",
"      Cutting zipper mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/18/42273\" title=\"picture 3\">",
"      Zipper fastener release with screwdriver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/56/26509\" title=\"table 1\">",
"      Comparison of commonly infiltrated local anesthetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_25_30101="Reteplase: Drug information";
var content_f29_25_30101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Reteplase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/23/30067?source=see_link\">",
"    see \"Reteplase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Retavase&reg; Half-Kit;",
"     </li>",
"     <li>",
"      Retavase&reg; Kit",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Retavase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thrombolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      STEMI:",
"     </b>",
"     I.V.: 10 units I.V. over 2 minutes, followed by a second dose 30 minutes later of 10 units I.V. over 2 minutes; withhold second dose if serious bleeding or anaphylaxis occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     All patients should receive 162-325 mg of chewable nonenteric coated aspirin as soon as possible and then daily. Administer concurrently with heparin 60 units/kg bolus (maximum: 4000 units) followed by continuous infusion of 12 units/kg/hour (maximum: 1000 units/hour) and adjust to aPTT target of 50-70 seconds (or 1.5-2 times the upper limit of control).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retavase&reg; Half-Kit: 10.4 units [contains polysorbate 80, sucrose 364 mg/vial; equivalent to reteplase 18.1 mg; one Reteplase&reg; vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retavase&reg; Kit: 10.4 units [contains polysorbate 80, sucrose 364 mg/vial; equivalent to reteplase 18.1 mg; two Retavase&reg; vials; supplied with diluents]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted dose should be administered I.V. over 2 minutes; no other medication should be added to the injection solution.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14180298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Bivalirudin, heparin",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ST-elevation myocardial infarction (STEMI); improvement of ventricular function; reduction of the incidence of CHF and the reduction of mortality following AMI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommended criteria for treatment (Antman, 2004): STEMI: Chest pain &ge;20 minutes duration, onset of chest pain within 12 hours of treatment (or within prior 12-24 hours in patients with continuing ischemic symptoms), and ST-segment elevation &gt;0.1 mV in at least two contiguous precordial leads or two adjacent limb leads on ECG or new or presumably new left bundle branch block (LBBB)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2973287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V.) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding is the most frequent adverse effect associated with reteplase. Heparin and aspirin have been administered concurrently with reteplase in clinical trials. The incidence of adverse events is a reflection of these combined therapies, and is comparable to comparison thrombolytics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Local: Injection site bleeding (5% to 49%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bleeding (2% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Bleeding (1% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Intracranial hemorrhage (0.8%), allergic/anaphylactoid reactions, cholesterol embolization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other adverse effects noted are frequently associated with MI (and therefore may or may not be attributable to Retavase&reg;) and include arrhythmia, AV block, cardiac arrest, cardiogenic shock, embolism, heart failure, hypotension, myocardial rupture, mitral regurgitation, pericardial effusion, pericarditis, pulmonary edema, recurrent ischemia, reinfarction, tamponade, thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active internal bleeding; history of cerebrovascular accident; recent intracranial or intraspinal surgery or trauma; intracranial neoplasm, arteriovenous malformations, or aneurysm; known bleeding diathesis; severe uncontrolled hypertension",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Rare anaphylactic reactions can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor all potential bleeding sites. If serious bleeding occurs, the infusion of reteplase and heparin should be stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions that increase bleeding risk: For the following conditions the risk of bleeding is higher with use of reteplase and should be weighed against the benefits of therapy: recent (within 10 days) major surgery (eg, CABG, obstetrical delivery, organ biopsy), recent puncture of noncompressible vessels, cerebrovascular disease, recent gastrointestinal or genitourinary bleeding, recent trauma including CPR, hypertension (systolic BP &gt;180 mm Hg and/or diastolic BP &gt;110 mm Hg), high likelihood of left heart thrombus (eg, mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, hemostatic defects including ones caused by severe renal or hepatic dysfunction, significant hepatic or renal dysfunction, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, septic thrombophlebitis or occluded AV cannula at seriously infected site, or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of location.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (MI): Appropriate use: Follow standard management for MI while infusing reteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin: Concurrent heparin anticoagulation may contribute to bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age (eg, &gt;75 years); increased risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intramuscular injections and nonessential handling of the patient should be avoided. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Thrombolytic Agents may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Whenever possible, avoid use of drotrecogin within 3 days of a thrombolytic agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. The risk of bleeding may be increased in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Retavase Half-Kit Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10.4 unit (1): $2605.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Retavase Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10.4 unit (1): $5211.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs of bleeding (hematuria, GI bleeding, gingival bleeding); CBC, PTT; ECG monitoring",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Pai Tong Xin (CL);",
"     </li>",
"     <li>",
"      Rapilysin (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IT, MT, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TR);",
"     </li>",
"     <li>",
"      Rui Tong Li (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reteplase is a nonglycosylated form of tPA produced by recombinant DNA technology using",
"     <i>",
"      E. coli",
"     </i>",
"     ; it initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Thrombolysis: 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 13-16 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces and urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Plasma: 250-450 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Comparison of Reteplase With Alteplase for Acute Myocardial Infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(16):1118-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/9340503/pubmed\" id=\"9340503\" target=\"_blank\">",
"        9340503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellis SG, Tendera M, de Belder MA, et al, &ldquo;Facilitated PCI in Patients With ST-Elevation Myocardial Infarction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(21):2205-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/18499565/pubmed\" id=\"18499565\" target=\"_blank\">",
"        18499565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keeley EC, Boura JA, and Grines CL, \"Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-Elevation Myocardial Infarction: Quantitative Review of Randomised Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9510):579-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/16488801/pubmed\" id=\"16488801\" target=\"_blank\">",
"        16488801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al, &ldquo;2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):172-209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/18191745/pubmed\" id=\"18191745\" target=\"_blank\">",
"        18191745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner FG, Hand M, Smith SC, et al, &ldquo;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2205-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/19942100/pubmed\" id=\"19942100\" target=\"_blank\">",
"        19942100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Van de Werf F, et al, &ldquo;Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(17):2130-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/12413372/pubmed\" id=\"12413372\" target=\"_blank\">",
"        12413372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor RE,  Brady W, Brooks SC, et al, &ldquo;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):787-817.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/20956226/pubmed\" id=\"20956226\" target=\"_blank\">",
"        20956226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ryan TJ, Anderson JK, Antman EM, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1996, 28(5):1328-428.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/8890834/pubmed\" id=\"8890834\" target=\"_blank\">",
"        8890834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smalling RW, Bode C, Kalbfleisch J, et al, &ldquo;More Rapid, Complete, and Stable Coronary Thrombolysis With Bolus Administration of Reteplase Compared With Alteplase Infusion in Acute Myocardial Infarction. RAPID Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 91(11):2725-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/7758177/pubmed\" id=\"7758177\" target=\"_blank\">",
"        7758177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, GUSTO V Investigators, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357:1905-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/25/30101/abstract-text/11425410/pubmed\" id=\"11425410\" target=\"_blank\">",
"        11425410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9857 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30101=[""].join("\n");
var outline_f29_25_30101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217795\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217796\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217828\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217799\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217800\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217780\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217765\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217782\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14180298\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217781\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973287\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217826\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217785\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217769\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299994\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217774\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217776\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447525\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217804\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323783\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217778\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217787\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217768\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217784\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9857|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/23/30067?source=related_link\">",
"      Reteplase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_25_30102="Intermediate case 8";
var content_f29_25_30102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intermediate case 8",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 98px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30102=[""].join("\n");
var outline_f29_25_30102=null;
var title_f29_25_30103="TdT staining ALL";
var content_f29_25_30103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymph node biopsy of lymphoblastic leukemia/lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph node biopsy shows positive staining for terminal deoxytransferase (TdT). Immunoperoxidase, 100x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30103=[""].join("\n");
var outline_f29_25_30103=null;
var title_f29_25_30104="Sickle hemoglobin polymer: Structure and functional properties";
var content_f29_25_30104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sickle hemoglobin polymer: Structure and functional properties",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30104/contributors\">",
"     Martin H Steinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30104/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30104/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/25/30104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In sickle hemoglobin (Hb S), a valine is substituted for glutamic acid on the surface of the Hb S molecule in the sixth codon of the beta globin chain (HBB glu6val). This change endows Hb S when deoxygenated with a new property: the capacity to polymerize. This new property conspires against an indispensable feature of the red cell: its pliability and deformability in spite of a very high intra-erythrocytic concentration of hemoglobin (normal: 32 to 34",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    polymerization of deoxy Hb S is the primary and indispensable event in the molecular pathogenesis of sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The polymer has the form of an elongated rope-like fiber which usually aligns with other fibers, forming a fascicle, and distorting the red cell into the classic crescent or sickle shape, among many other abnormal shapes, and resulting in a marked decrease in cell deformability. Hb S can polymerize when deoxygenated and depolymerize when reoxygenated infinitely; however, the sickle erythrocyte membrane can withstand only a finite number of these cycles before it is irreversibly injured and recognized via the many abnormal \"sickle\" shapes that circulate in patients.",
"   </p>",
"   <p>",
"    Polymerization alone does not account for the pathophysiology of sickle cell disease. Subsequent changes in red cell membrane structure and function, disordered red cell volume control, increased red cell adherence to vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], misregulation of vasoactivity, and inflammation also contribute to sickle vasoocclusion and hemolysis that are the hallmarks of sickle cell disease. In genetics these are called pleiotropic effects, because they go beyond the immediate consequences of the abnormal gene.",
"   </p>",
"   <p>",
"    The polymerization process and the modulating factors will be reviewed here. Other issues relating to the sickling process and an overview of structure and function of hemoglobin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE SICKLE FIBER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following deoxygenation, Hb S containing cells assume a variety of distorted shapes readily appreciated by light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"UTD.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ) and even more clearly by scanning electron microscopy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77366 \" href=\"UTD.htm?43/18/44335\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61255 \" href=\"UTD.htm?10/36/10818\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/5\">",
"     5",
"    </a>",
"    ]. Studies at higher resolution using transmission electron microscopy have provided information concerning the structure and packing of the sickle fiber. X-ray diffraction studies subsequently refined the structure at a resolution of 0.2 nm (2.0 &Aring;) and provided information on molecular orientation and contacts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyses of deoxygenated sickle cells reveal the presence of parallel bundles of long fibers that are oriented along the axis of sickling [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In cells that assume a holly leaf shape, bundles of Hb S fibers point in the direction of each projection. Image reconstruction studies have provided data on the three-dimensional structure of the fiber [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basic polymer structure is a double-stranded filament. Each strand is a string of deoxy Hb S beads aligned in head to tail (or axial) array. Seven filaments combine into a fiber organized such that adjacent double strands have antiparallel orientation. The twisted rope-like structure is composed of an inner core of four strands surrounded by a sheath of 10 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/15\">",
"       15",
"      </a>",
"      ]. The double strands are slightly twisted in the fiber. Stretching of the outer strands in the fiber limits its size to seven pairs.",
"     </li>",
"     <li>",
"      A critical series of experiments that established the identification of the double strands as assembly units of the sickle fiber [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/16\">",
"       16",
"      </a>",
"      ] was the use of naturally occurring mutants in hybridized co-polymerization experiments (binary mixtures), first involving beta-globin mutants [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Later, these experiments were extended to alpha-globin mutants [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Individual fibers have an elliptical cross-section of about 23 nm by 18 nm [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/14\">",
"       14",
"      </a>",
"      ]. Since hemoglobin tetramers are globular molecules with a diameter of about 5.5 nm, one can calculate that up to about 15 molecules could be packed into a cross-sectional area.",
"     </li>",
"     <li>",
"      Longitudinal views reveal a subtle but regular helix structure, in keeping with the elliptical cross section [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/14\">",
"       14",
"      </a>",
"      ]. The helix has a high pitch with a periodicity of about 300 nm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intermolecular bonding",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, our understanding of the intermolecular binding of sickle hemoglobin has come from structural analysis of crystals of deoxy Hb S and studies of the solubility of mixtures of Hb S with hemoglobins A, A2, F, and alpha- and beta-globin mutants, and more recently using genetically engineered site-directed globin mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/1,20-23\">",
"     1,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the fiber, the Hb S tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/betaS2)",
"    </span>",
"    is oriented in such a way that the 6(A3) val of one of the two beta subunits (beta2) forms a hydrophobic contact with a complementary or acceptor site at 70(E14) ala, 85(F1) phe and 88(F4) leu on the beta1 subunit of the adjacent partner strand. Similar but not identical contacts are made with 6 val of beta2 in the other strand: 70(E14) ala, 73(E17) asp, and 88(F4) leu.",
"   </p>",
"   <p>",
"    Importantly, the 6 val of the beta1 subunit does not participate in intermolecular bonding, a feature predicted by binary mixtures involving the beta6 and beta2 sites. Studies in Hb S Leiden, Makassar and Deer Lodge have determined that only one beta chain in the Hb S tetramer was involved in a contact area of the bonding fiber, since their mutations did not affect polymerization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. Furthermore, the contact between the beta2 beta 6 val and an acceptor site on the partner strand is only possible when Hb S is in the T or deoxy conformation. R or oxygenated molecules cannot fit into the polymeric structure.",
"   </p>",
"   <p>",
"    There are other amino acid residues that affect bonding and polymerization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The beta-globin mutants that alter gel formation tend to be on the beta1 or \"trans\" subunit and involve either lateral contacts between partners of the double strand or axial contacts between members of a single strand. Alpha chain contacts tend to be either axial or between double strands.",
"     </li>",
"     <li>",
"      The amino acid residue beta 6 val is not indispensable for polymerization. Replacement of beta 6 glu (in Hb A) by another hydrophobic residue, isoleucine, results in a hemoglobin",
"      <span class=\"nowrap\">",
"       (alpha2/beta6Ile2)",
"      </span>",
"      that polymerizes even more readily than Hb S [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Solutions of Hb S and Hb D Los Angeles (HBB glu121gln) polymerize much more readily than a solution containing only Hb S [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interactions involving the amino acid residues of alpha 114pro and beta 87thr also appear to be important for polymerization [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/27\">",
"       27",
"      </a>",
"      ]. As with other contacts that stabilize the polymer, amino acid replacement results in a marked decrease in polymerization, which has important implications for gene therapy. Beta 87 thr is not a direct interaction site for beta 6 val in deoxy Hb S polymers [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/28\">",
"       28",
"      </a>",
"      ]. It does, however, play a critical role in formation of the hydrophobic acceptor pocket, which then promotes protein-protein interactions, facilitating formation of stable nuclei and polymers of deoxy Hb S.",
"     </li>",
"     <li>",
"      Studies with recombinant hemoglobins indicate that substitutions at remote sites (alpha 6ala, alpha 75Y and beta 121arg) exhibit additive, enhanced polymerization properties [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SICKLE HEMOGLOBIN POLYMERIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerization of sickle hemoglobin involves the self-association of identical molecules; no accessory molecules are involved. As a result, the assembly process obeys classic chemical rules of kinetics and thermodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/1,30,31\">",
"     1,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Solubility of Hb S",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerization of Hb S is a simple phase change from sol to gel. When a gelled solution of deoxygenated Hb S is carefully examined, large polymers (fibers) and free tetramers can be readily demonstrated, but species of intermediate size cannot be detected. Thus, the equilibrium between sol and gel can be studied by measurement of the concentration of free hemoglobin in solution after segregating the polymer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/1,32,33\">",
"     1,32,33",
"    </a>",
"    ]. This concentration is referred to as the CSAT: the concentration of Hb S in the supernatant of the gel.",
"   </p>",
"   <p>",
"    For pure deoxy Hb S at pH 7, 20&ordm;C, the solubility is 20",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    considerably lower than the concentration of hemoglobin inside the red cell. The rate of polymerization of deoxy Hb S is dependent upon the Hb S concentration. Polymerization-induced membrane activation of volume-regulating transport systems, leading to enhanced dehydration, results in the presence of a substantial population of very dense cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This dehydration of sickle erythrocytes involves increased activity of the membrane K-Cl cotransporter and the calcium-dependent (Gardos) potassium channel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H17#H17\">",
"     \"Specific therapies for sickle cell disease\", section on 'Mechanism of erythrocyte dehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The solubility of Hb S is also affected by a number of parameters other than concentration such as fractional oxygenation, pH, temperature, ionic strength, organic phosphates, and the presence of non-S hemoglobins. Attempts have been made to quantitate these variables, assuming a homogeneous distribution among the erythrocyte population, and to calculate the mean polymer fraction in patient erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the severity of the clinical course cannot be predicted from these measurements due to the heterogeneous distribution of these parameters in individual red cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fractional oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the structure of Hb S is nearly identical with that of Hb A when not polymerized, the two hemoglobins have identical oxygen binding curves in dilute solution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/37\">",
"     37",
"    </a>",
"    ]. However, at concentrations above the solubility of deoxy Hb S, the O2 binding curve is progressively right shifted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Since Hb S polymerizes only when it is in the T quaternary conformation, the polymer binds O2 non-cooperatively and with low affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles of thermodynamic linkage dictate that O2 affinity is lowered in direct proportion to the amount of polymer formed. Furthermore, because of the reciprocal relationship between oxygen binding and polymerization, the solubility of Hb S increases directly with O2 saturation. Fully oxygenated molecules of Hb S or partially oxygenated molecules that assume the R conformation cannot be incorporated into the polymer but indirectly lower the solubility because their large excluded volume greatly increases the chemical activity of the coexisting T-state molecules, thereby favoring their aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/42\">",
"     42",
"    </a>",
"    ]. This nonideality consideration applies equally well to the solubility of mixtures of S and non-S hemoglobins and is a particularly important determinant of polymer formation at very high hemoglobin concentrations, as in red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The solubility of deoxy Hb S is lowest between pH 6.0 and 7.2 and rises quite sharply at higher and lower pH values [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Thus, in the extra-erythrocytic pH range 6.5 to 7.5 (corresponding to intracellular pH of 7.0 and 7.2), the alkaline Bohr effect is enhanced in concentrated solutions of Hb S and in sickle erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/46\">",
"     46",
"    </a>",
"    ]. On the other hand, alkalosis, by shifting the equilibrium toward the oxy conformation, tends to retard sickling, but also impairs oxygen release.",
"   </p>",
"   <p>",
"    The significant difference in the slope of the Bohr effect in sickle cells means that a decrease in blood pH below 7.4 in tissue capillaries yields twice the normal decrease in oxygen affinity and a large release of oxygen from red cells, increasing significantly their risk of sickling. Clinically, this means that even mild transient acidosis (with a corresponding drop of intracellular pH) would be hazardous for patients with sickling disorders. The latter was actually experimentally and unethically demonstrated when patients with sickle cell anemia were infused with low pH isotonic solutions, and painful crises ensued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerization of Hb S is an endothermic process consistent with the importance of hydrophobic interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/43,47,48\">",
"     43,47,48",
"    </a>",
"    ]. Polymer formation is therefore entropically driven, resulting from the release of ordered water molecules from the surface of free hemoglobin. Sickle polymers are melted by cooling. Thus, a temperature jump is a simple and effective way of initiating polymerization, thereby enabling kinetic measurements. While low temperatures inhibit sickle polymerization, the therapeutic use of cooling is not advisable, since vasoconstriction and other vasoocclusive effects might predominate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ionic strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;The solubility of deoxy Hb S depends upon salt and buffer conditions. At salt concentrations spanning the physiologic range, solubility increases with ionic strength, but decreases markedly at high ionic strength [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Organic phosphates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary modulator of O2 affinity in the red cell is 2,3 bisphosphoglycerate (2,3-BPG). An increase in red cell 2,3-BPG favors Hb S polymerization in three ways: lowered O2 affinity; a reduction in intracellular pH (both of which increase deoxy Hb S); and a direct effect on the conformation of deoxy Hb S [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. High concentrations of adenosine may promote the sickling phenomenon both in vitro and in vivo through adenosine A",
"    <sub>",
"     2B",
"    </sub>",
"    receptor-mediated induction of 2,3-BPG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Non-S hemoglobins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of particular and practical importance is the effect of coexistent Hbs F, A and C. Information on the copolymerization of Hb S with these hemoglobins has provided important insights into the pathogenesis and clinical severity of the various sickle syndromes, including sickle cell anemia with increased levels of Hb F, Hb S-beta(0) thalassemia, Hb S-beta(+) thalassemia, Hb SC disease, and Hb AS (sickle trait).",
"   </p>",
"   <p>",
"    The solubility of a mixture of equal amounts of Hb S and Hb A (and that of Hb S and Hb C) is only about 40 percent higher than that of Hb S alone. In this mixture, half of the hemoglobin is comprised of asymmetric hybrid tetramers (eg,",
"    <span class=\"nowrap\">",
"     alpha2/betaS/betaA).",
"    </span>",
"    Since only one of the two beta 6 valines is engaged in an intermolecular contact, there is a 50 percent chance that the hybrid tetramer will enter the polymer in such a way that all the proper contacts are made. Indeed, incorporation of the hybrid",
"    <span class=\"nowrap\">",
"     (alpha2/betaS/betaA)",
"    </span>",
"    into the sickle polymer has been experimentally documented [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, the Hb A tetramers",
"    <span class=\"nowrap\">",
"     (alpha2/beta2),",
"    </span>",
"    which comprise 25 percent of the mixture, fail to be incorporated into the polymer. Nevertheless, by virtue of their excluded volume, the solubility is further lowered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to hemoglobins A and C, Hb F and Hb A2",
"    <strong>",
"     inhibit",
"    </strong>",
"    polymerization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, the hybrid tetramers",
"    <span class=\"nowrap\">",
"     (alpha2/betaS/gamma)",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     (alpha2/betaS/delta)",
"    </span>",
"    fail to be incorporated into the sickle polymer. Since Hb F",
"    <span class=\"nowrap\">",
"     (alpha2/gamma2)",
"    </span>",
"    affects polymerization by means of the asymmetrical hybrid",
"    <span class=\"nowrap\">",
"     (alpha2/betaS/gamma),",
"    </span>",
"    the inhibition is trans to the beta 6 val contact [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/44,55\">",
"     44,55",
"    </a>",
"    ]. Gamma 87 is one of the important inhibitory sites for both Hb F and Hb A2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/54\">",
"     54",
"    </a>",
"    ]. This residue constitutes one of the lateral contacts in the double strand of the sickle fiber.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Kinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polymerization of sickle hemoglobin is a remarkably dynamic event. Measurements of the kinetics of polymer formation, both in pure Hb S solutions and in sickle erythrocytes, have provided insights into the pathogenesis of vasoocclusive crises [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. These studies led directly to information on the nucleation mechanism responsible for fiber formation, and studies on intact red cells have provided an explanation at the molecular level of the morphologic changes that are observed following the deoxygenation of cells, both in vitro and in vivo. Understanding the kinetics of polymerization has provided a novel and workable approach to the assessment of new antisickling therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link\">",
"     \"Specific therapies for sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hemoglobin S solution studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course for polymerization of a concentrated solution of Hb S can be monitored after either rapid removal of ligand (eg, by photolysis) or by rapidly increasing the temperature of deoxy Hb S, taking advantage of the markedly endothermic nature of the process. The formation of sickle fibers can be documented by a variety of physicochemical techniques including turbidity, light scattering, calorimetry, and nuclear magnetic resonance spectroscopy. The subsequent alignment of fibers is best monitored by measurement of birefringence.",
"   </p>",
"   <p>",
"    Following ligand removal or a temperature change, there is a measurable lag time before a signal reflecting the presence of detectable polymer. The progress of polymer formation is exponential. During the lag time, there is insufficient amount of polymer to provide a signal, due to limitations of sensitivity of the methods used for monitoring.",
"   </p>",
"   <p>",
"    The number of molecules in the nucleus appears to be proportional to the slope of the concentration dependence of the delay time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/30\">",
"     30",
"    </a>",
"    ]. Nevertheless, when molecular crowding is taken into account (ie, nonideality) the slope of the concentration dependency of the delay time predicts a nucleus of about 15 molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/42\">",
"     42",
"    </a>",
"    ]. Aggregates smaller than the critical nucleus are thermodynamically unfavored. In contrast, once the nucleus is formed, subsequent addition of molecules is highly favored and fiber growth becomes very rapid (approximately 250 hemoglobin tetramers per second) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies using statistical thermodynamic modeling have suggested that there are two pathways for the nucleation of sickle hemoglobin fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homogeneous nucleation refers to nucleation of individual fibers occurring in the bulk solution phase.",
"     </li>",
"     <li>",
"      Heterogeneous nucleation refers to nucleation occurring on the surface of existing polymers, which leads to autocatalytic formation of fibers, and therefore the delay period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In highly concentrated solutions of deoxy Hb S, homogeneous nucleation is favored. Polarizing microscopy reveals multiple domains of polymers giving rise to birefringent spherulites. These are probably the tactoids first observed in solutions of deoxy Hb S [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In less concentrated solutions of deoxy Hb S, heterogeneous nucleation predominates, leading to fewer domains of aligned sickle fibers. Studies with video-enhanced differential interference contrast microscopy show that fibers originate both from centers that produce many radially distributed fibers and on the surface of preexisting fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intracellular studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extension of the equilibrium and kinetic studies of polymerization to erythrocytes is greatly complicated by marked heterogeneity of sickle erythrocytes, due to a wide range of oxygen affinity, an even wider distribution of intracellular hemoglobin concentration (20 to 50",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    and the heterogeneous distribution of 2,3-BPG and Hb F. However, when these variables are taken into account, the delay times of sickle red cells and the amount of polymer per cell at equilibrium are remarkably close to what is encountered in hemoglobin solutions, indicating that the cytosolic surface of the red cell membrane has no significant effect on the delay time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The kinetics of polymerization plays a critical role in the rheology and morphology of circulating red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/64\">",
"     64",
"    </a>",
"    ]. Because the range of transit times in the microcirculation is short relative to the range of delay times of sickle erythrocytes, the great majority (perhaps 95 percent) of cells fail to form polymers during their flow through arterioles and capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/64\">",
"     64",
"    </a>",
"    ]. In contrast, if these cells were equilibrated at the oxygen tensions in the microcirculation, virtually all of them would contain polymer and as a result would have markedly decreased deformability. Thus, kinetics is the critical determinant of cell shape and morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When sickle cells are deoxygenated slowly, they form classic elongated (sickle) shapes. This is due to homogeneous nucleation in which one domain propagates by fiber growth and alignment to distort the cell into a classic sickle shape. With somewhat more rapid deoxygenation, a few independent domains will induce a more irregular shape [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When deoxygenation is rapid, multiple spherulitic domains result in a granular or cobblestone texture (\"sack of potatoes\" aspect) with no gross distortion of cell shape.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the shape of the sickled cell is so dependent upon the number of independent polymer domains, it is possible to convert a holly leaf cell into an elongated sickle shape by partial reoxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/66\">",
"     66",
"    </a>",
"    ]. The distortion of cell shape by projections of aligned Hb S fibers plays a critical role in the pathogenesis of the membrane lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vascular occlusion by sickle cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cells had been thought to obstruct the microcirculation by interrupting flow, due to decreased deformability at the level of capillaries. In reality, this phenomenon is much more complicated, and only three types of obstruction have been documented with videomicroscopy of ex vivo or in vivo microcirculatory preparations or other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irreversibly sickled cells are fixed in their deformed shape because of membrane damage and do not return to normal shape when oxygenated even though their Hb S might not be polymerized. Such irreversibly sickled cells can obstruct at the level of the precapillary sphincter [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/68\">",
"       68",
"      </a>",
"      ], a phenomenon that is probably of very low frequency.",
"     </li>",
"     <li>",
"      Sickled cell can be trapped in the small adherent post-capillary venules of ex vivo microcirculatory preparations when these are bedecked by adherent young sickle cells (",
"      <a class=\"graphic graphic_figure graphicRef80615 \" href=\"UTD.htm?10/44/10945\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dense sickle cells can obstruct retinal capillaries and the choroid microcirculation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/69-71\">",
"       69-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Animal models have demonstrated that deoxygenation of sickle cells produces entrapment of dense sickled cells in the pulmonary circulation, but not adhesion [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TNF-alpha can induce the adhesion and promote vasoocclusion of sickle cells in retinal capillaries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the mechanisms by which red cells containing sickle polymer can induce pathology are complex; they may also interact with other pleiotropic effects of sickle cells (such as endothelial adhesion and dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30104/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]), and might vary organ by organ. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nature of the gene defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;In sickle hemoglobin (Hb S), a valine is substituted for glutamic acid on the surface of the Hb S molecule in the sixth codon of the beta globin chain (HBB glu6val). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     How the gene defect induces hemoglobin polymerization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the sickle hemoglobin polymer fiber, the Hb S tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/betaS2)",
"    </span>",
"    is oriented in such a way that the 6(A3) val of one of the two beta subunits forms a hydrophobic contact with a complementary or acceptor site on the beta1 subunit of the adjacent partner strand. Similar but not identical contacts are made with 6 val of beta2 in the other strand. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Sickle hemoglobin polymerization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The contact between the beta2 beta 6 val and an acceptor site on the partner strand is only possible when Hb S is in the deoxy conformation. Oxygenated molecules cannot fit into the polymeric structure. Thus, polymer formation is possible only with deoxygenated sickle hemoglobin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Interference with sickle hemoglobin polymerization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb F inhibits Hb S polymerization. This observation has served as the impetus to increase levels of Hb F in patients with sickle cell disease in order to obtain clinical improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Fetal hemoglobin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/1\">",
"      Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990; 40:63.",
"     </a>",
"    </li>",
"    <li>",
"     Ferrone F, Nagel RL. Sickle hemoglobin polymerization. In: Disorders of hemoglobin: Genetics, pathophysiology, clinical management, Steinberg MH, Forget BG, Higgs D, Nagel RL (Eds), Cambridge University Press, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/3\">",
"      Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A 1989; 86:3356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/4\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/5\">",
"      White JG. Ultrastructural features of erythrocyte and hemoglobin sickling. Arch Intern Med 1974; 133:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/6\">",
"      Wishner BC, Ward KB, Lattman EE, Love WE. Crystal structure of sickle-cell deoxyhemoglobin at 5 A resolution. J Mol Biol 1975; 98:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/7\">",
"      Padlan EA, Love WE. Refined crystal structure of deoxyhemoglobin S. I. Restrained least-squares refinement at 3.0-A resolution. J Biol Chem 1985; 260:8272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/8\">",
"      Harrington DJ, Adachi K, Royer WE Jr. The high resolution crystal structure of deoxyhemoglobin S. J Mol Biol 1997; 272:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/9\">",
"      White JG. The fine structure of sickled hemoglobin in situ. Blood 1968; 31:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/10\">",
"      Bertles JF, D&ouml;bler J. Reversible and irreversible sickling: a distinction by electron microscopy. Blood 1969; 33:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/11\">",
"      Edelstein SJ, Telford JN, Crepeau RH. Structure of fibers of sickle cell hemoglobin. Proc Natl Acad Sci U S A 1973; 70:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/12\">",
"      Dykes G, Crepeau RH, Edelstein SJ. Three-dimensional reconstruction of the fibres of sickle cell haemoglobin. Nature 1978; 272:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/13\">",
"      Garrell RL, Crepeau RH, Edelstein SJ. Cross-sectional views of hemoglobin S fibers by electron microscopy and computer modeling. Proc Natl Acad Sci U S A 1979; 76:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/14\">",
"      Dykes GW, Crepeau RH, Edelstein SJ. Three-dimensional reconstruction of the 14-filament fibers of hemoglobin S. J Mol Biol 1979; 130:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/15\">",
"      Rodgers DW, Crepeau RH, Edelstein SJ. Pairings and polarities of the 14 strands in sickle cell hemoglobin fibers. Proc Natl Acad Sci U S A 1987; 84:6157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/16\">",
"      Nagel RL, Johnson J, Bookchin RM, et al. Beta-chain contact sites in the haemoglobin S polymer. Nature 1980; 283:832.",
"     </a>",
"    </li>",
"    <li>",
"     Nagel RL, Bookchin RM. Studies on the Supramolecular Structure of the Hemoglobin S Polymer. In: Molecular Interactions of Hemoglobin, Poyart C, Rosa J (Eds), Institut national de la sante et de la recherche medicale, Paris l977. Vol 70.",
"    </li>",
"    <li>",
"     Nagel RL, Bookchin RM. Areas of Interaction in the HbS Polymer. In: Biochemical and Clinical Aspects of Hemoglobin Abnormalities, Caughey WS (Ed), Academic Press, New York l978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/19\">",
"      Benesch RE, Yung S, Benesch R, et al. alpha-Chain contacts in the polymerisation of sickle haemogloblin. Nature 1976; 260:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/20\">",
"      Watowich SJ, Gross LJ, Josephs R. Analysis of the intermolecular contacts within sickle hemoglobin fibers: effect of site-specific substitutions, fiber pitch, and double-strand disorder. J Struct Biol 1993; 111:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/21\">",
"      Himanen JP, Popowicz AM, Manning JM. Recombinant sickle hemoglobin containing a lysine substitution at Asp-85(alpha): expression in yeast, functional properties, and participation in gel formation. Blood 1997; 89:4196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/22\">",
"      Adachi K, Pang J, Konitzer P, Surrey S. Polymerization of recombinant hemoglobin F gamma E6V and hemoglobin F gamma E6V, gamma Q87T alone, and in mixtures with hemoglobin S. Blood 1996; 87:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/23\">",
"      Adachi K, Pang J, Reddy LR, et al. Polymerization of three hemoglobin A2 variants containing Val6 and inhibition of hemoglobin S polymerization by hemoglobin A2. J Biol Chem 1996; 271:24557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/24\">",
"      Bookchin RM, Nagel RL. Conformational requirements for the polymerization of hemoglobin S: studies of mixed liganded hybrids. J Mol Biol 1973; 76:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/25\">",
"      Baudin-Chich V, Pagnier J, Marden M, et al. Enhanced polymerization of recombinant human deoxyhemoglobin beta 6 Glu----Ile. Proc Natl Acad Sci U S A 1990; 87:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/26\">",
"      Adachi K, Kim J, Ballas S, et al. Facilitation of Hb S polymerization by the substitution of Glu for Gln at beta 121. J Biol Chem 1988; 263:5607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/27\">",
"      Ho C, Willis BF, Shen TJ, et al. Roles of alpha 114 and beta 87 amino acid residues in the polymerization of hemoglobin S: implications for gene therapy. J Mol Biol 1996; 263:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/28\">",
"      Reddy LR, Reddy KS, Surrey S, Adachi K. Role of beta87 Thr in the beta6 Val acceptor site during deoxy Hb S polymerization. Biochemistry 1997; 36:15992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/29\">",
"      Li X, Mirza UA, Chait BT, Manning JM. Systematic enhancement of polymerization of recombinant sickle hemoglobin mutants: implications for transgenic mouse model for sickle cell anemia. Blood 1997; 90:4620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/30\">",
"      Eaton WA, Hofrichter J. Hemoglobin S gelation and sickle cell disease. Blood 1987; 70:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/31\">",
"      Briehl RW. Sickle-cell hemoglobin. Encyclopedia of Human Biology 1991; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/32\">",
"      Bertles JF, Rabinowitz R, D&ouml;bler J. Hemoglobin interaction: modification of solid phase composition in the sickling phenomenon. Science 1970; 169:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/33\">",
"      Briehl RW, Ewert S. Effects of pH, 2,3-diphosphoglycerate and salts on gelation of sickle cell deoxyhemoglobin. J Mol Biol 1973; 80:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/34\">",
"      Canessa M. Red cell volume-related ion transport systems in hemoglobinopathies. Hematol Oncol Clin North Am 1991; 5:495.",
"     </a>",
"    </li>",
"    <li>",
"     Brugnara C. Red Cell Membrane pathology in sickle cells. In: Disorders of Hemoglobin: Genetics, pathophysiology, clinical management, Steinberg MH, Forget BG, Higgs D, Nagel RL (Eds), Cambridge University Press, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/36\">",
"      Poillon WN, Kim BC, Castro O. Intracellular hemoglobin S polymerization and the clinical severity of sickle cell anemia. Blood 1998; 91:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/37\">",
"      Bunn HF. The interaction of sickle hemoglobin with DPG, CO 2 and with other hemoglobins: formation of asymmetrical hybrids. Adv Exp Med Biol 1972; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/38\">",
"      Gill SJ, Skold R, Fall L, et al. Aggregation effects on oxygen binding of sickle cell hemoglobin. Science 1978; 201:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/39\">",
"      Benesch RE, Edalji R, Kwong S, Benesch R. Oxygen affinity as an index of hemoglobin S polymerization: a new micromethod. Anal Biochem 1978; 89:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/40\">",
"      Gill SJ, Benedict RC, Fall L, et al. Oxygen binding to sickle cell hemoglobin. J Mol Biol 1979; 130:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/41\">",
"      Sunshine HR, Hofrichter J, Ferrone FA, Eaton WA. Oxygen binding by sickle cell hemoglobin polymers. J Mol Biol 1982; 158:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/42\">",
"      Minton AP. Non-ideality and the thermodynamics of sickle-cell hemoglobin gelation. J Mol Biol 1977; 110:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/43\">",
"      Ross PD, Hofrichter J, Eaton WA. Thermodynamics of gelation of sickle cell deoxyhemoglobin. J Mol Biol 1977; 115:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/44\">",
"      Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem 1977; 252:3414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/45\">",
"      Briehl RW. Gelation of sickle cell hemoglobin. IV. Phase transitions in hemoglobin S gels: separate measures of aggregation and solution--gel equilibrium. J Mol Biol 1978; 123:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/46\">",
"      Ueda Y, Nagel RL, Bookchin RM. An increased Bohr effect in sickle cell anemia. Blood 1979; 53:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/47\">",
"      Ross PD, Hofrichter J, Eaton WA. Calorimetric and optical characterization of sickle cell hemoglobin gelation. J Mol Biol 1975; 96:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/48\">",
"      Magdoff-Fairchild B, Poillon WN, Li T, Bertles JF. Thermodynamic studies of polymerization of deoxygenated sickle cell hemoglobin. Proc Natl Acad Sci U S A 1976; 73:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/49\">",
"      Poillon WN, Bertles JF. Deoxygenated sickle hemoglobin. Effects of lyotropic salts on its solubility. J Biol Chem 1979; 254:3462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/50\">",
"      Adachi K, Ozguc M, Asakura T. Nucleation-controlled aggregation of deoxyhemoglobin S. Participation of hemoglobin A in the aggregation of deoxyhemoglobin S in concentrated phosphate buffer. J Biol Chem 1980; 255:3092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/51\">",
"      Swerdlow PH, Bryan RA, Bertles JF, et al. Effect of 2, 3-diphosphoglycerate on the solubility of deoxy-sickle hemoglobin. Hemoglobin 1977; 1:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/52\">",
"      Poillon WN, Kim BC. 2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood 1990; 76:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/53\">",
"      Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 2011; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/54\">",
"      Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979; 76:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/55\">",
"      Bookchin RM, Nagel RL, Balazs T. Role of hybrid tetramer formation in gelation of haemoglobin S. Nature 1975; 256:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/56\">",
"      Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci U S A 1974; 71:4864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/57\">",
"      Hofrichter J, Ross PD, Eaton WA. Supersaturation in sickle cell hemoglobin solutions. Proc Natl Acad Sci U S A 1976; 73:3035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/58\">",
"      Samuel RE, Salmon ED, Briehl RW. Nucleation and growth of fibres and gel formation in sickle cell haemoglobin. Nature 1990; 345:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/59\">",
"      Ferrone FA, Hofrichter J, Sunshine HR, Eaton WA. Kinetic studies on photolysis-induced gelation of sickle cell hemoglobin suggest a new mechanism. Biophys J 1980; 32:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/60\">",
"      Hofrichter J. Kinetics of sickle hemoglobin polymerization. III. Nucleation rates determined from stochastic fluctuations in polymerization progress curves. J Mol Biol 1986; 189:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/61\">",
"      HARRIS JW. Studies on the destruction of red blood cells. VIII. Molecular orientation in sickle cell hemoglobin solutions. Proc Soc Exp Biol Med 1950; 75:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/62\">",
"      Coletta M, Hofrichter J, Ferrone FA, Eaton WA. Kinetics of sickle haemoglobin polymerization in single red cells. Nature 1982; 300:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/63\">",
"      Goldberg MA, Lalos AT, Bunn HF. The effect of erythrocyte membrane preparations on the polymerization of sickle hemoglobin. J Biol Chem 1981; 256:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/64\">",
"      Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science 1987; 237:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/65\">",
"      Horiuchi K, Ballas SK, Asakura T. The effect of deoxygenation rate on the formation of irreversibly sickled cells. Blood 1988; 71:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/66\">",
"      Horiuchi K, Asakura T. Oxygen promotes sickling of SS cells. Ann N Y Acad Sci 1989; 565:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/67\">",
"      Cheung AT, Chen PC, Larkin EC, et al. Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood 2002; 99:3999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/68\">",
"      Kurantsin-Mills J, Jacobs HM, Lessin LS. Sickle cell vaso-occlusion in an animal model; intravital microscopy and radionuclide imaging of selective sequestration of dense cells. Prog Clin Biol Res 1987; 240:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/69\">",
"      Lutty GA, Phelan A, McLeod DS, et al. A rat model for sickle cell-mediated vaso-occlusion in retina. Microvasc Res 1996; 52:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/70\">",
"      Lutty GA, McLeod DS, Pachnis A, et al. Retinal and choroidal neovascularization in a transgenic mouse model of sickle cell disease. Am J Pathol 1994; 145:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/71\">",
"      Lutty GA, Merges C, McLeod DS, et al. Nonperfusion of retina and choroid in transgenic mouse models of sickle cell disease. Curr Eye Res 1998; 17:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/72\">",
"      Aldrich TK, Dhuper SK, Patwa NS, et al. Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. J Appl Physiol 1996; 80:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/73\">",
"      Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30104/abstract/74\">",
"      Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002; 99:1564.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7069 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-C3EBFED581-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30104=[""].join("\n");
var outline_f29_25_30104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE SICKLE FIBER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intermolecular bonding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SICKLE HEMOGLOBIN POLYMERIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Solubility of Hb S",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fractional oxygenation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - pH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Temperature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ionic strength",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Organic phosphates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Non-S hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hemoglobin S solution studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intracellular studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vascular occlusion by sickle cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nature of the gene defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      How the gene defect induces hemoglobin polymerization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Interference with sickle hemoglobin polymerization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7069\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7069|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/18/44335\" title=\"diagnostic image 1\">",
"      Sickle cell scanning EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7069|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/44/10945\" title=\"figure 1\">",
"      Vessel occlusion sickle cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7069|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/42/1703\" title=\"picture 1\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/36/10818\" title=\"picture 2\">",
"      Irreversible sickle cell TEM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_25_30105="Pediatric intracranial germ cell tumors";
var content_f29_25_30105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pediatric intracranial germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Jack M Su, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30105/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/25/30105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germ cell tumors (GCTs) are classified as extragonadal if there is no evidence of a primary tumor in either the testes or the ovaries. Extragonadal GCTs typically arise in midline locations, and specific sites vary with age. In adults, the most common sites are the anterior mediastinum, retroperitoneum, and the pineal and suprasellar regions. In infants and young children, intracranial GCTs and sacrococcygeal teratomas are more common than other locations.",
"   </p>",
"   <p>",
"    Intracranial GCTs are discussed here. Sacrococcygeal teratomas and extragonadal GCTs arising in the mediastinum and retroperitoneum are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17894?source=see_link\">",
"     \"Sacrococcygeal germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America and Europe, intracranial GCTs represent 0.5 to 3 percent of pediatric central nervous system (CNS) tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, these tumors are substantially more frequent in Japan and other Asian countries, with a reported incidence of up to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peak incidence of intracranial GCT is during the second decade of life, with a median age at diagnosis of 10 to 12 years. There is a male preponderance of between 2:1 to 3:1, especially with tumors in the pineal region [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various theories have been proposed to explain the origin of extragonadal GCTs. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link&amp;anchor=H2#H2\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\", section on 'Histogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Molecular biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpubertal malignant GCTs in both the testis and extragonadal sites are frequently associated with a gain of isochromosome 12p. In contrast, this abnormality has not been consistently observed in young children with sacrococcygeal teratomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17894?source=see_link&amp;anchor=H5#H5\">",
"     \"Sacrococcygeal germ cell tumors\", section on 'Genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"     \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited, studies suggest that the isochromosome 12p abnormality frequently is present in children with extragonadal GCTs. In a series of 34 cases that included two patients with CNS germinomas and five with yolk sac tumors within sacrococcygeal teratomas, isochromosome 12p was present in 53 percent of patients age 5 to 16 years and in 29 percent of patients younger than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study restricted to 19 children with intracranial malignant GCTs, chromosome imbalances were observed in 17 (89 percent), and the characteristic isochromosome 12p was observed in 11 children (58 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/5\">",
"     5",
"    </a>",
"    ]. In a second study, 6 of 15 patients (40 percent) with pineal gland GCTs had a gain of chromosome 12p [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A recent genomic analysis of pediatric intracranial germ cell tumors reported distinct mRNA profile, miRNA profile, and chromosome copy number variations in germinomas versus non-germinomatous GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/7\">",
"     7",
"    </a>",
"    ]. Further genomic characterization of pediatric intracranial GCTs will hopefully improve our understanding of their biology and identify novel therapeutic targets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the World Health Organization classification system, intracranial GCTs are divided into germinomas and non-germinomatous GCTs (NGGCTs) (",
"    <a class=\"graphic graphic_table graphicRef82711 \" href=\"UTD.htm?8/29/8667\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/8\">",
"     8",
"    </a>",
"    ]. NSGGCTs include embryonal carcinoma, endodermal sinus tumor (also known as yolk sac tumor), choriocarcinoma, teratoma (immature and mature), and mixed tumors with more than one element. Germinomas comprise 60 to 65 percent of all pediatric intracranial GCTs. Approximately 25 percent of NGGCTs are mixed and contain more than one histologic component [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracranial GCTs can be further defined by tumor markers secreted into the cerebrospinal fluid (CSF) and serum, as well as by the presence of histochemical markers on tumor cells (",
"    <a class=\"graphic graphic_table graphicRef81974 \" href=\"UTD.htm?14/11/14524\">",
"     table 2",
"    </a>",
"    ). Secreted tumor markers measured in the CSF and serum include alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (beta-hCG), and immunohistochemistry is used to detect placental alkaline phosphatase (PLAP) and c-Kit on tumor cells.",
"   </p>",
"   <p>",
"    Histologically, pure germinomas are composed of large polygonal undifferentiated cells with abundant cytoplasm arranged in nests separated by bands of connective tissue. The histologic appearance of NGGCTs varies depending upon the specific cell types present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/8\">",
"     8",
"    </a>",
"    ]. Infiltrating small lymphocytes are often present and can obscure the diagnosis, especially in small biopsy specimens.",
"   </p>",
"   <p>",
"    Intracranial GCTs can also be divided into \"secreting\" and \"nonsecreting\" tumors. Secreting tumors are commonly defined as GCTs with CSF AFP &gt;10",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    (or above the institutional normal range)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a CSF beta-hCG level &gt;50 int.",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    Secreting GCTs are generally considered to behave more aggressively and carry a poorer prognosis than nonsecreting GCTs.",
"   </p>",
"   <p>",
"    Pure germinomas generally are associated with absent AFP and beta-hCG levels in both CSF and serum. Although an elevated AFP in either the serum or CSF effectively rules out a pure germinoma, a minority of germinomas are associated with elevated beta-hCG levels in the CSF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/9\">",
"     9",
"    </a>",
"    ]. The source of the elevated beta-hCG is thought to be syncytiotrophoblasts that are associated with germinomas. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Beta-HCG secreting germinomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another classification system commonly used in Japan separates intracranial GCTs into \"good\", \"intermediate\", and \"poor prognosis\" groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/10\">",
"     10",
"    </a>",
"    ]. Pure germinomas and mature teratomas are included in the \"good prognosis\" group. Choriocarcinoma, yolk sac tumor, embryonal carcinoma, and mixed NGGCTs composed mainly of these three histologies are included in the \"poor prognosis\" group, with all other tumors included in the \"intermediate prognosis\" group. Patients in the \"good prognosis\" have over-all survival exceeding 90 percent, while patients in the \"intermediate\" and \"poor prognosis\" groups have over-all survival rates of approximately 70 and 40 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric intracranial GCTs arise almost exclusively from midline locations. The two most frequent sites are the pineal gland and the suprasellar regions, with pineal tumors occurring nearly twice as often as suprasellar GCTs. Pediatric intracranial GCTs can also arise in the basal ganglia, thalamus, cerebral hemisphere, and cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In five to ten percent of cases, children present with tumors at both pineal and suprasellar locations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; these tumors are usually pure germinomas. Tumor seeding or multiple tumor nodules along the lateral and third ventricles are observed in about 10 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms of children with intracranial GCTs depend upon the location of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H431567392\">",
"    <span class=\"h3\">",
"     Pineal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pineal tumors typically cause obstructive hydrocephalus. Children present with signs of increased intracranial pressure (headache, vomiting, papilledema, lethargy, somnolence) in 25 to 50 percent of cases. Other symptoms associated with pineal GCTs and obstructive hydrocephalus include ataxia, behavioral changes, and decline in academic performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16714?source=see_link\">",
"     \"Pineal gland masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroopthalmologic abnormalities (especially paralysis of upward gaze and convergence) are present in up to 50 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link&amp;anchor=H9#H9\">",
"     \"Supranuclear disorders of gaze in children\", section on 'Parinaud syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocrinopathies are rarely associated with pineal tumors at diagnosis, although diabetes insipidus is sometimes observed and may indicate occult tumor involvement of the floor of the fourth ventricle and the suprasellar area [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H431567399\">",
"    <span class=\"h3\">",
"     Suprasellar tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suprasellar GCTs most commonly present with",
"    <span class=\"nowrap\">",
"     hypothalamic/pituitary",
"    </span>",
"    dysfunctions, including diabetes insipidus, delayed pubertal development or precocious puberty, isolated growth hormone deficiency, or other aspects of hypopituitarism (central hypothyroidism, adrenal insufficiency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suprasellar GCTs can also cause ophthalmologic abnormalities such as decreased visual acuity from chiasmic or optic nerve compression or visual field deficit (classically, bitemporal hemianopsia). Children with suprasellar GCTs often have chronic subtle symptoms, and their tumors are diagnosed incidentally on imaging studies performed for unrelated reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination is needed to establish a definitive diagnosis of an intracranial GCT and to ascertain the histologic subtype. A tissue sample should be obtained unless surgery cannot be performed safely. Surgery to obtain tissue for diagnosis is MANDATORY for patients with normal CSF and serum AFP and beta-hCG, as a pure germinoma or a mature teratoma must be distinguished from other benign and malignant lesions, including pineal primitive neuroectodermal tumor (PNET), ependymoma (pineal location), craniopharyngioma, Langerham cell histiocytosis (suprasellar location), low-grade glioma, hamartoma, or metastatic disease from extra-cranial tumors (either location). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An elevated level of AFP in either the CSF or serum is sufficient to classify a tumor as a NGGCT, although tumor tissue is useful for prognostic classification and biologic studies. Patients with an elevated beta-hCG (&gt;50",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    but normal AFP should undergo surgery if possible to distinguish a beta-hCG secreting germinoma from an immature teratoma or a choriocarcinoma, as the latter are considered NGGCTs and need more aggressive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the preferred imaging technique for diagnosis and staging, although computed tomography (CT) is also very sensitive in detecting suprasellar and pineal GCTs.",
"   </p>",
"   <p>",
"    On MRI, pediatric intracranial GCTs appear isointense or hypointense on T1 sequences and hyperintense on T2 sequences. These tumors typically show homogeneous enhancement with gadolinium or heterogeneous enhancement if cysts are present. Imaging characteristics of the histologic subtypes are similar, and MRIs cannot reliably distinguish germinomas from NGGCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI of the entire spine is imperative for adequate staging of pediatric intracranial GCTs, since 10 to 15 percent of patients will have leptomeningeal spread diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between germinomas and NGGCTs is critical, since children with germinomas have a more favorable prognosis and require less intensive therapy than those with NGGCTs. Tumor markers, such as AFP and beta-hCG, are helpful in making this distinction, although histologic examination is required for a definitive diagnosis.",
"   </p>",
"   <p>",
"    Pure germinomas and mature teratomas typically present with normal levels of AFP and beta-hCG in both serum and CSF. Some histologically confirmed germinomas have elevated beta-hCG levels that are presumed to be due to beta-hCG secreting syncytiotrophoblasts. In such cases, elevations of serum beta-hCG are generally limited (&lt;50",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    although some tumors have levels &gt;100",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Beta-HCG secreting germinomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Any tumor with an elevated AFP (&gt;10",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    or higher than the institutional normal range) can be assumed to contain elements of endodermal sinus tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immature teratoma. If a histologic diagnosis is not possible because surgery is contraindicated, such a patient should be treated as having a NGGCT. Pure endodermal sinus tumor or pure choriocarcinomas are often associated with dramatic elevations in AFP (&gt;500",
"    <span class=\"nowrap\">",
"     microg/L)",
"    </span>",
"    or beta-hCG (&gt;1000",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    whereas immature teratomas have less dramatic elevations of AFP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta-hCG. A serum AFP &gt;1000",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    has recently been identified as a poor prognostic indicator [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], but since a significant proportion of these tumors have mixed components, it is not yet feasible to use tumor markers for risk stratification without a tissue diagnosis.",
"   </p>",
"   <p>",
"    Measurement of AFP and beta-hCG in the CSF is more sensitive than serum levels in detecting abnormalities. However, discordant serum and CSF tumor marker results have been observed, and both serum and CSF tumor markers should be obtained in the absence of clinical contraindications. If a lumbar puncture can be safely performed, lumbar CSF is considered more accurate for tumor markers and cytology than ventricular CSF. However, if a lumbar puncture is contraindicated, then tumor markers from ventricular CSF can be used for diagnostic purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     CSF cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF cytology should be obtained during staging of an intracranial GCT whenever a lumbar puncture can be safely performed. Even if MRI of the spine does not show evidence of tumor involvement, patients with positive CSF cytology are considered to have metastatic intracranial GCTs and should receive craniospinal irradiation (CSI) as part of their treatment. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining tissue to establish a histologic diagnosis should be strongly considered for children with a suspected intracranial GCT, unless the morbidity of the procedure outweighs the benefit. In addition, immediate neurosurgical intervention is indicated for obstructive hydrocephalus from a pineal mass or for acute visual deterioration from a suprasellar mass. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis and staging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgical biopsies often yield only a small sample, and this can lead to an inaccurate tissue diagnosis. As an example, in a mixed GCT that contains both germinoma and non-germinomatous components, a small biopsy may only include an area of pure germinoma. When the tissue diagnosis is discordant from the CSF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum markers, treatment should be based upon the result that is associated with the most malignant histology and worst prognosis. As an example, a tissue diagnosis of a pure germinoma would be inconsistent with an elevated AFP, and such a patient should be considered as having a NGGCT. Conversely, if the tissue diagnosis reveals elements of a NGGCT, despite normal AFP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta-hCG levels, the patient should be treated as having a NGGCT and not a pure germinoma.",
"   </p>",
"   <p>",
"    Gross total resection at diagnosis is indicated only for patients with mature teratoma confirmed by histology and normal tumor markers, since surgery is curative and no further interventions are required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/10,11,18\">",
"     10,11,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because pure germinomas are exquisitely sensitive to radiation therapy, a gross total resection of localized germinomas is generally not recommended because of the risk of surgical complications and because pure germinomas are exquisitely sensitive to radiation therapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Germinomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefit of gross total tumor resection in localized NGGCTs has not been established; several large series have not confirmed that macroscopic tumor resection improves the final outcome of children with intracranial NGGCT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/11,16,17\">",
"     11,16,17",
"    </a>",
"    ]. Instead of pursuing a macroscopic resection of a NGGCT at the initial surgery, such a procedure may be performed more safely after tumor reduction by chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (RT). (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Nongerminomatous GCTs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With continued evolution of chemotherapy and radiation therapy for pediatric intracranial GCTs, the role of neurosurgery for diagnosing and treating these tumors also continues to be discussed and reexamined. A publication from the Second International Symposium on Central Nervous System Germ Cell Tumors provides an excellent review on neurosurgery recommendations in pediatric intracranial GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Germinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric intracranial germinomas are exquisitely sensitive to radiation. Most contemporary series have reported long-term progression free survival (PFS) rates &gt;90 percent for children with localized, pure germinomas after radiation therapy (RT) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/20-26\">",
"     20-26",
"    </a>",
"    ]. Historically, children with localized germinomas received 36 Gy craniospinal irradiation (CSI) and a boost to the primary tumor for a total of 50 to 54 Gy.",
"   </p>",
"   <p>",
"    The main issue with RT is the incidence of clinically significant late neurocognitive and endocrine complications. Thus, clinical research has focused on reducing both the dose and volume of radiation, without compromising the excellent survival rate. Germinomas are also highly sensitive to chemotherapy, and more recent studies have added chemotherapy and reduced the dose of RT in an effort to further minimize late complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of cranial irradiation\", section on 'Late reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An optimal treatment strategy that is emerging from recent trials for localized germinoma is to use combined modality therapy. The available clinical data suggest that localized germinoma is optimally treated with RT and chemotherapy. The RT volume should include both the tumor and the ventricles volume (including the fourth ventricle). The current consensus is that the whole ventricle radiation dose should be 21 to 24 Gy, with an additional boost to the primary tumor for a total of 40 to 45 Gy. Treatment with chemotherapy should precede irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Craniospinal irradiation RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The propensity of intracranial GCTs to develop subventricular seeding and subsequent craniospinal metastases provided the original rationale for craniospinal irradiation (CSI). CSI is no longer considered necessary for children with localized germinomas as long as they are treated with a combined modality approach that uses chemotherapy and irradiation based upon the response to chemotherapy. CSI is only recommended for patients with disseminated germinomas based upon MRI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CSF findings. Current recommendations include treating bifocal tumors as localized tumors if the MRI of the spine and the CSF cytology are negative.",
"   </p>",
"   <p>",
"    A change from the historical approach of using 36 Gy CSI was initially supported by a series of 49 patients, in which the dose of CSI was reduced to 30 Gy and the dose of radiation to the primary tumor was decreased from 50 to 45 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/20\">",
"     20",
"    </a>",
"    ]. Using these modified radiation doses, the PFS was 87 percent. Several other studies subsequently demonstrated that replacing CSI with whole-brain or whole-ventricle irradiation in patients with localized germinomas resulted in a spinal failure rate of less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/10,22,27-33\">",
"     10,22,27-33",
"    </a>",
"    ]. The patterns of relapse following whole-brain or whole-ventricle RT compared to CSI were not significantly different, suggesting that recurrent germinomas after RT are unlikely to be related to a volume reduction in RT.",
"   </p>",
"   <p>",
"    Additional data supporting the efficacy of a reduced dose of CSI come from an interim report of results from the SIOP CNS GCT 96 study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/34\">",
"     34",
"    </a>",
"    ]. For patients with metastatic germinoma, the five-year PFS was 98 percent after chemotherapy, 24 Gy CSI, and a 16 Gy tumor boost (total RT dose to the primary tumor 40 Gy), suggesting that the dose of CSI can be further reduced when given in combination with chemotherapy even for patients with metastatic germinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Whole ventricular RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CSI is not required in children with localized germinoma, retrospective data suggest that eliminating whole-ventricle irradiation and limiting RT to the tumor increases the recurrence rate in patients with localized germinomas.",
"   </p>",
"   <p>",
"    The importance of whole-ventricle RT was demonstrated in a series of 35 patients with localized germinomas who did not receive CSI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/31\">",
"     31",
"    </a>",
"    ]. In this cohort, 21 children were treated with whole-ventricle irradiation, none of whom developed recurrent disease. In contrast, 5 of 14 (36 percent) who received only focal tumor irradiation had recurrent tumors within the ventricular system but outside the primary treatment field. Similarly, in a second series, the recurrence rate for patients receiving localized irradiation without ventricular coverage was higher than in those receiving CSI (28 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/20\">",
"     20",
"    </a>",
"    ]. Additional studies in support of whole-ventricular RT for localized germinomas are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platinum-based chemotherapy regimens have a high level of activity against extracranial GCTs in children. As in adults with advanced GCTs, the most widely used combinations are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (BEJ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the excellent response and survival outcome of children with extracranial GCTs, neoadjuvant chemotherapy was given to children with localized intracranial germinomas, followed by a reduced dose and volume of RT, in an effort to minimize toxicity. Several small series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/35-41\">",
"     35-41",
"    </a>",
"    ] showed excellent tumor response to chemotherapy (partial and complete response rates nearing 100 percent) and suggested that neoadjuvant chemotherapy allowed the reduction of both the dose and volume of RT in children with localized germinomas without compromising PFS.",
"   </p>",
"   <p>",
"    While it is clear that the addition of chemotherapy obviated the need for CSI in children with localized germinomas, larger studies with longer follow-up observed that elimination of whole-ventricle RT increased the tumor recurrence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/16,34,42-44\">",
"     16,34,42-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 60 children with localized germinomas, neoadjuvant chemotherapy followed by 40 Gy focal RT to the tumors resulted in an eight-year EFS of 83 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/42\">",
"       42",
"      </a>",
"      ]. Eight of 10 recurrences occurred outside the RT field, in the periventricular area [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the SIOP CNS GCT 96 study, 183 children with localized germinomas received either chemotherapy plus 40 Gy focal RT or 24 Gy CSI with a 16 Gy tumor boost without chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/34\">",
"       34",
"      </a>",
"      ]. The EFS for children receiving chemotherapy and focal RT was less than for those receiving RT to a larger field without chemotherapy (85 versus 96 percent). In the children who received chemotherapy plus focal RT, 5 of 12 recurrences (42 percent) were outside the RT field.",
"     </li>",
"     <li>",
"      A preliminary report of a phase II study from the Japanese CNS GCT Study Group described outcomes in 123 children with localized germinomas, most of whom were treated with chemotherapy followed by focal RT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/16\">",
"       16",
"      </a>",
"      ]. The recurrence rate was higher in patients who received chemotherapy plus focal RT compared to those who received chemotherapy plus whole ventricle RT (28 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the promise of neoadjuvant chemotherapy, further reduction of the total RT dose below 40 Gy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elimination of whole-ventricle RT should only be done within the context of a prospective randomized trial. The upcoming COG trial for localized germinoma will examine the efficacy of reducing the dose of whole ventricle irradiation in patients whose tumors had complete responses to chemotherapy and compare to historical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Chemotherapy only",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nearly all children with localized germinomas respond to chemotherapy, treatment with chemotherapy alone has resulted in unacceptable tumor recurrence rates. In two series that included a total of 64 children with pure germinomas, recurrent disease eventually developed in 48 and 58 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The Third International CNS Germ Cell Tumor Study also confirmed that a chemotherapy-only approach led to inferior event-free survival compared to radiation-containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Beta-HCG secreting germinomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure germinomas can contain syncytiotrophoblasts that produce and secrete beta-HCG. Early reports suggested that beta-hCG secreting germinomas had a higher relapse rate than non-secreting pure germinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/25,43\">",
"     25,43",
"    </a>",
"    ]. However, subsequent reanalysis of the data found that the increased rate of recurrence of beta-HCG secreting germinomas was primarily related to elimination of whole-brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    whole-ventricle RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/9,11,16,48-50\">",
"     9,11,16,48-50",
"    </a>",
"    ], and no recurrences were observed in patients with beta-HCG secreting germinomas who received at least whole-ventricle RT.",
"   </p>",
"   <p>",
"    The major concern in patients with presumed beta-hCG secreting germinomas is whether or not the intracranial GCT actually is a pure germinoma, or whether there also is an element of choriocarcinoma or immature teratoma present. Although there is no consensus on the optimal approach for children with histologically proven germinoma and a beta-hCG &gt;50",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    a repeat surgery for a more generous tumor sample may be warranted to exclude an NGGCT and avoid overtreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contemporary series of patients with pure germinomas, recurrences are most commonly encountered in patients who received neoadjuvant chemotherapy and a reduced dose of RT. The majority of these patients can be salvaged with radiation with or without chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/16,34,42,44,47\">",
"     16,34,42,44,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most recurrent germinomas remain sensitive to chemotherapy, and retreatment with the original regimen is a viable strategy to reinduce a complete remission. For patients who received RT to a reduced volume, CSI is considered the standard of care.",
"   </p>",
"   <p>",
"    For patients who already received CSI, myeloablative high-dose chemotherapy with autologous stem cell rescue can be considered, followed by additional RT if it can be safely tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nongerminomatous GCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because NGGCTs are less common than germinomas and includes several histologic subtypes (",
"    <a class=\"graphic graphic_table graphicRef81974 \" href=\"UTD.htm?14/11/14524\">",
"     table 2",
"    </a>",
"    ), available clinical data are sparse and difficult to interpret. Nongerminomatous GCTs (NGGCTs) are relatively insensitive to radiation. In small series, children with NGGCTs who were treated with RT alone (CSI and a boost to the tumor) had overall survival (OS) rates of 20 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/2,3,11,55\">",
"     2,3,11,55",
"    </a>",
"    ]. Combining neoadjuvant chemotherapy with RT significantly improved outcomes in children with NGGCT, although results remain inferior to that for patients with germinoma. In the absence of a prospective randomized study, chemotherapy followed by CSI remains the standard of care for all children with intracranial NGGCTs.",
"   </p>",
"   <p>",
"    Almost all the chemotherapy regimens contain a platinum compound (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and some groups add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to this combination. The most common approach uses four to six cycles of chemotherapy prior to second-look surgery. This is followed by RT, including CSI (30 to 36 Gy) and a tumor boost (for a total of 54 to 60 Gy).",
"   </p>",
"   <p>",
"    Multiple studies have shown that neoadjuvant chemotherapy prior to RT results in long-term survival of 60 to 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/17,56,57\">",
"     17,56,57",
"    </a>",
"    ]. As an example, the most recent update of the SIOP CNS GCT 96 protocol reported progression-free survival (PFS) of 67 percent in 102 patients with localized NGGCT who received chemotherapy and focal RT. In 28 patients with metastatic NGGCT, PFS was 72 percent using chemotherapy followed by 30 Gy CSI and 24 Gy boost to the primary tumor and macroscopic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/17\">",
"     17",
"    </a>",
"    ]. Overall, Japanese results are similar, although there is some evidence that outcomes are better in intermediate-prognosis patients and worse in the poor-prognosis subset [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/11,16,58\">",
"     11,16,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of AFP elevation is an adverse prognostic indicator in children with intracranial NGGCTs. In the SIOP CNS GCT 96 study, patients with normal AFP levels had a progression-free survival (PFS) of 80 percent, while those with an AFP of 100 to 1000",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    and those with an AFP &gt;1000",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    showed PFS of 60 and 33 percent, respectively. In contrast, the degree of beta-HCG elevation in children with intracranial NGGCTs does not appear to have an impact on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/17,40\">",
"     17,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Craniospinal irradiation in NGGCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of craniospinal irradiation (CSI) in children with localized NGGCTs is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/10,16,17,58\">",
"     10,16,17,58",
"    </a>",
"    ]. In the SIOP CNS GCT 96 study, 25 recurrences were observed in 102 children who had been treated with chemotherapy and whole ventricle irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there was only one isolated spine recurrence outside of the radiation field. In the largest Japanese series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/16\">",
"     16",
"    </a>",
"    ], the majority of recurrences in patients who received whole ventricle irradiation also occurred in the radiation field.",
"   </p>",
"   <p>",
"    Although the importance of CSI for localized NGGCTs remains controversial, radiation to the primary tumor site and ventricles does appear to be important. In patients treated with chemotherapy alone, recurrences have been observed in 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/46,59,60\">",
"     46,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the upcoming COG trial for children with NGGCT, patients with localized tumors who achieve a CR either by chemotherapy alone or chemotherapy and second-look surgery will receive radiation to the whole ventricle plus a tumor boost, instead of CSI. This design will hopefully determine prospectively the significance of craniospinal irradiation for localized NGGCT .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Extent of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no definitive data that suggest that gross total resection of NGGCT at the time of diagnosis improves either progression-free or overall survival.",
"   </p>",
"   <p>",
"    However, resection of residual tumors after chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT may have a role, with a few small series suggesting that gross total resection may improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/57,58,61\">",
"     57,58,61",
"    </a>",
"    ]. At resection, the majority of residual masses in children with intracranial NGGCTs after chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT are mature teratoma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     necrotic/scar",
"    </span>",
"    tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/19\">",
"     19",
"    </a>",
"    ], although viable tumor cells have also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/57,58,61-64\">",
"     57,58,61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary results from two large series suggest that residual masses after chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation in children with intracranial NGGCTs are associated with a poorer prognosis. In SIOP CNS GCT 96 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/17\">",
"     17",
"    </a>",
"    ], 16 of 34 patients with residual masses after chemotherapy and radiation ultimately experienced recurrent disease, leading to a PFS of 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/17\">",
"     17",
"    </a>",
"    ]. In a study in children with intermediate-prognosis NGGCTs from the Japanese GCT Study Group, the tumor recurrence rate was worse for those with residual masses after chemoradiotherapy compared to those without a residual mass (32 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although more definitive data are needed, strong consideration should be given for second-look surgery in children who have residual tumors after chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Growing teratoma syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"growing teratoma syndrome\" is defined as a solitary enlarging tumor, with normal or declining AFP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta-HCG, which upon resection proves to be composed entirely of a mature teratoma. This is a well-defined event that occurs in up to 10 percent of patients with extracranial NGGCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/65\">",
"     65",
"    </a>",
"    ]. This phenomenon is rare in children with intracranial NGGCTs, occurring in less than 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/66-73\">",
"     66-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link&amp;anchor=H15#H15\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Growing teratoma syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'Significance of teratoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection of a probable growing mature teratoma should be attempted in children with intracranial NGGCTs who experience an enlarging solitary tumor during or shortly after chemotherapy or RT despite normalization of tumor markers. This approach avoids subjecting patients to more intensive treatments due to a mistaken diagnosis of tumor recurrence or progression.",
"   </p>",
"   <p>",
"    Surgical resection for a growing mature teratoma is the only curative intervention, since these lesions do not respond to chemotherapy or RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Recurrent NGGCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for children with recurrent intracranial NGGCTs is poor. Nearly all will have received chemotherapy and RT as their initial treatment.",
"   </p>",
"   <p>",
"    High-dose chemotherapy with autologous stem cell rescue has been attempted with variable success [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30105/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Identification of novel effective agents for intracranial NGGCTs is urgently needed to improve clinical outcome for children with these heterogeneous and challenging tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial germ cell tumors (GCTs) are rare brain tumors that typically arise in the pineal or suprasellar regions. Intracranial GCTS include a number of histologic tumor types (",
"    <a class=\"graphic graphic_table graphicRef82711 \" href=\"UTD.htm?8/29/8667\">",
"     table 1",
"    </a>",
"    ); the primary distinction is between germinomas and nongerminomatous germ cell tumors (NGGCTs), since NGGCTs require more intensive chemotherapy and craniospinal irradiation. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Histologic classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless clinically contraindicated, the initial evaluation of a child with a suspected intracranial GCT should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroimaging with MRI with and without contrast to include the head and the entire spine (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Neuroimaging'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Measurement of alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (beta-hCG) in both serum and cerebrospinal fluid (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Tumor markers'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cytology from cerebrospinal fluid (see",
"      <a class=\"local\" href=\"#H13\">",
"       'CSF cytology'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Biopsy of the tissue mass to establish a histologic diagnosis (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Surgery'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment of germinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized pure germinoma, we suggest initial treatment with whole ventricle radiation therapy (RT) with a boost field to the primary tumor (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Germinomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The current standard approach is treatment to the whole ventricles with a dose of 21 to 24 Gy, followed by a boost to the tumor for a total tumor dose of 40 to 45 Gy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Whole ventricular RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several recent small series have demonstrated that in children with localized germinomas who achieved a complete remission after neoadjuvant chemotherapy, radiation dose to the tumor and whole ventricle can be further reduced without compromising the excellent progression-free survival in these patients. An upcoming Children&rsquo;s Oncology Group (COG) study will prospectively determine whether neoadjuvant chemotherapy followed by reduced radiation to the tumor and whole ventricle will maintain the excellent historical outcome. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Neoadjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the majority of germinomas are sensitive to chemotherapy, a chemotherapy alone approach has been associated with an unacceptable rate of relapse. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Chemotherapy only'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Craniospinal irradiation is indicated only for patients with multifocal germinomas or metastatic tumors, as identified by MRI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CSF cytology or those tumors who do not demonstrate either a complete response or partial response to chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment of NGGCTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with NGGCTs, we recommend neoadjuvant chemotherapy followed by craniospinal irradiation, rather than either RT or chemotherapy alone (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). This approach has resulted in long-term survival in 60 to 70 percent of cases. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Nongerminomatous GCTs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal chemotherapy regimen has not been defined. The available data indicate that platinum-based regimens, such as those used in other gonadal and extragonadal germ cell tumors, are effective. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Nongerminomatous GCTs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available data indicate that RT is an essential component of initial treatment. The current standard of care is to use craniospinal irradiation. The reduction of the volume of irradiation to include only the tumor bed and the ventricular volume, after a complete tumor response to neoadjuvant chemotherapy, will be prospectively tested in an upcoming COG trial. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Craniospinal irradiation in NGGCTs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with residual masses after chemotherapy and RT, second look surgery should be strongly considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with both germinomas and NGGCTs should be encouraged to participate in prospective clinical trials whenever possible.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/1\">",
"      Echevarr&iacute;a ME, Fangusaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. Oncologist 2008; 13:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/2\">",
"      Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 1985; 63:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/3\">",
"      Hoffman HJ, Otsubo H, Hendrick EB, et al. Intracranial germ-cell tumors in children. J Neurosurg 1991; 74:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/4\">",
"      Palmer RD, Foster NA, Vowler SL, et al. Malignant germ cell tumours of childhood: new associations of genomic imbalance. Br J Cancer 2007; 96:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/5\">",
"      Schneider DT, Zahn S, Sievers S, et al. Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol 2006; 19:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/6\">",
"      Rickert CH, Simon R, Bergmann M, et al. Comparative genomic hybridization in pineal germ cell tumors. J Neuropathol Exp Neurol 2000; 59:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/7\">",
"      Wang HW, Wu YH, Hsieh JY, et al. Pediatric primary central nervous system germ cell tumors of different prognosis groups show characteristic miRNome traits and chromosome copy number variations. BMC Genomics 2010; 11:132.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenblum MK, Nakazato Y, Matsutani M. CNS germ cell tumors. In: WHO Classification of Tumours of the Central Nervous System, 3rd, Louis D, Ohgaki H, Wiestler O, Cavenee WK (Eds), WHO Publication Center, Albany, NY 2007. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/9\">",
"      Ogino H, Shibamoto Y, Takanaka T, et al. CNS germinoma with elevated serum human chorionic gonadotropin level: clinical characteristics and treatment outcome. Int J Radiat Oncol Biol Phys 2005; 62:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/10\">",
"      Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997; 86:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/11\">",
"      Matsutani M, Japanese Pediatric Brain Tumor Study Group. Combined chemotherapy and radiation therapy for CNS germ cell tumors--the Japanese experience. J Neurooncol 2001; 54:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/12\">",
"      Kim DI, Yoon PH, Ryu YH, et al. MRI of germinomas arising from the basal ganglia and thalamus. Neuroradiology 1998; 40:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/13\">",
"      Tamaki N, Lin T, Shirataki K, et al. Germ cell tumors of the thalamus and the basal ganglia. Childs Nerv Syst 1990; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/14\">",
"      Packer RJ, Cohen BH, Cooney K, Coney K. Intracranial germ cell tumors. Oncologist 2000; 5:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/15\">",
"      Liang L, Korogi Y, Sugahara T, et al. MRI of intracranial germ-cell tumours. Neuroradiology 2002; 44:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/16\">",
"      Matsutani M. Treatment of intracranial germ cell tumors: the second phase II study of Japanese GCT Study Group. J Neurooncol 2008; 10:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/17\">",
"      Calaminus G, Frappaz D, Kortmann R, et al. Localized and metastatic nongerminoma treated according to the SIOP CNS GCT 96 protocol: update on risk profiles and outcome. J Neurooncol 2008; 10:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/18\">",
"      Sawamura Y, de Tribolet N, Ishii N, Abe H. Management of primary intracranial germinomas: diagnostic surgery or radical resection? J Neurosurg 1997; 87:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/19\">",
"      Souweidane MM, Krieger MD, Weiner HL, Finlay JL. Surgical management of primary central nervous system germ cell tumors: proceedings from the Second International Symposium on Central Nervous System Germ Cell Tumors. J Neurosurg Pediatr 2010; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/20\">",
"      Bamberg M, Kortmann RD, Calaminus G, et al. Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89. J Clin Oncol 1999; 17:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/21\">",
"      Borg M. Germ cell tumours of the central nervous system in children-controversies in radiotherapy. Med Pediatr Oncol 2003; 40:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/22\">",
"      Haddock MG, Schild SE, Scheithauer BW, Schomberg PJ. Radiation therapy for histologically confirmed primary central nervous system germinoma. Int J Radiat Oncol Biol Phys 1997; 38:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/23\">",
"      Hardenbergh PH, Golden J, Billet A, et al. Intracranial germinoma: the case for lower dose radiation therapy. Int J Radiat Oncol Biol Phys 1997; 39:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/24\">",
"      Wolden SL, Wara WM, Larson DA, et al. Radiation therapy for primary intracranial germ-cell tumors. Int J Radiat Oncol Biol Phys 1995; 32:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/25\">",
"      Sawamura Y, Ikeda J, Shirato H, et al. Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer 1998; 34:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/26\">",
"      Jensen AW, Laack NN, Buckner JC, et al. Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma. Int J Radiat Oncol Biol Phys 2010; 77:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/27\">",
"      Dattoli MJ, Newall J. Radiation therapy for intracranial germinoma: the case for limited volume treatment. Int J Radiat Oncol Biol Phys 1990; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/28\">",
"      Aoyama H, Shirato H, Kakuto Y, et al. Pathologically-proven intracranial germinoma treated with radiation therapy. Radiother Oncol 1998; 47:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/29\">",
"      Linstadt D, Wara WM, Edwards MS, et al. Radiotherapy of primary intracranial germinomas: the case against routine craniospinal irradiation. Int J Radiat Oncol Biol Phys 1988; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/30\">",
"      Sugiyama K, Uozumi T, Arita K, et al. Clinical evaluation of 33 patients with histologically verified germinoma. Surg Neurol 1994; 42:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/31\">",
"      Haas-Kogan DA, Missett BT, Wara WM, et al. Radiation therapy for intracranial germ cell tumors. Int J Radiat Oncol Biol Phys 2003; 56:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/32\">",
"      Rogers SJ, Mosleh-Shirazi MA, Saran FH. Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol 2005; 6:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/33\">",
"      Shikama N, Ogawa K, Tanaka S, et al. Lack of benefit of spinal irradiation in the primary treatment of intracranial germinoma: a multiinstitutional, retrospective review of 180 patients. Cancer 2005; 104:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/34\">",
"      Calaminus G, Alapetite C, Frappaz D, et al. Outcome of localized and metastatic germinoma treated according to SIOP CNS GCT 96. J Neurooncol 2008; 10:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/35\">",
"      Allen JC, DaRosso RC, Donahue B, Nirenberg A. A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system. Cancer 1994; 74:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/36\">",
"      Allen JC, Kim JH, Packer RJ. Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. J Neurosurg 1987; 67:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/37\">",
"      Buckner JC, Peethambaram PP, Smithson WA, et al. Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. J Clin Oncol 1999; 17:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/38\">",
"      Fouladi M, Grant R, Baruchel S, et al. Comparison of survival outcomes in patients with intracranial germinomas treated with radiation alone versus reduced-dose radiation and chemotherapy. Childs Nerv Syst 1998; 14:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/39\">",
"      Douglas JG, Rockhill JK, Olson JM, et al. Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas. J Pediatr Hematol Oncol 2006; 28:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/40\">",
"      Kretschmar C, Kleinberg L, Greenberg M, et al. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2007; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/41\">",
"      Khatua S, Dhall G, O'Neil S, et al. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer 2010; 55:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/42\">",
"      Alapetite C, Patte C, Frappaz D, et al. Long-term follow-up of intracranial germinoma treated with primary chemotherapy followed by focal radiation treatment: The SFOP-90 experience. Neurooncol 2005; 7:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/43\">",
"      Aoyama H, Shirato H, Ikeda J, et al. Induction chemotherapy followed by low-dose involved-field radiotherapy for intracranial germ cell tumors. J Clin Oncol 2002; 20:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/44\">",
"      Alapetite C, Brisse H, Patte C, et al. Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neuro Oncol 2010; 12:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/45\">",
"      Kellie SJ, Boyce H, Dunkel IJ, et al. Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach. Pediatr Blood Cancer 2004; 43:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/46\">",
"      Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol 1996; 14:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/47\">",
"      da Silva NS, Cappellano AM, Diez B, et al. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 2010; 54:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/48\">",
"      Shibamoto Y, Takahashi M, Sasai K. Prognosis of intracranial germinoma with syncytiotrophoblastic giant cells treated by radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/49\">",
"      Shirato H, Aoyama H, Ikeda J, et al. Impact of margin for target volume in low-dose involved field radiotherapy after induction chemotherapy for intracranial germinoma. Int J Radiat Oncol Biol Phys 2004; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/50\">",
"      Matsutani M. Treatment for intracranial germinoma: Final results of the Japanese Study Group. Neurooncology 2005; 7:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/51\">",
"      Mahoney DH Jr, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J Clin Oncol 1996; 14:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/52\">",
"      Baranzelli M, Pichon F, Patte C, et al. High-dose etoposide and thio-TEPA for recurrent intracranial malignant germ cell tumours. Experiences of SFOP (the French Society of Pediatric Oncology). Childs Nerv Syst 1999; 14:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/53\">",
"      Modak S, Gardner S, Dunkel IJ, et al. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 2004; 22:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/54\">",
"      Bouffet E. The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors. Pediatr Blood Cancer 2010; 54:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/55\">",
"      Fuller BG, Kapp DS, Cox R. Radiation therapy of pineal region tumors: 25 new cases and a review of 208 previously reported cases. Int J Radiat Oncol Biol Phys 1994; 28:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/56\">",
"      Robertson PL, DaRosso RC, Allen JC. Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neurooncol 1997; 32:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/57\">",
"      Calaminus G, Bamberg M, Harms D, et al. AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89. Neuropediatrics 2005; 36:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/58\">",
"      Ogawa K, Toita T, Nakamura K, et al. Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multiinstitutional retrospective analysis of 41 patients. Cancer 2003; 98:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/59\">",
"      Calaminus G, Bamberg M, Baranzelli MC, et al. Intracranial germ cell tumors: a comprehensive update of the European data. Neuropediatrics 1994; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/60\">",
"      Kellie SJ, Boyce H, Dunkel IJ, et al. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol. J Clin Oncol 2004; 22:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/61\">",
"      Ushio Y, Kochi M, Kuratsu J, et al. Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases. J Neurosurg 1999; 90:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/62\">",
"      Friedman JA, Lynch JJ, Buckner JC, et al. Management of malignant pineal germ cell tumors with residual mature teratoma. Neurosurgery 2001; 48:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/63\">",
"      Weiner HL, Lichtenbaum RA, Wisoff JH, et al. Delayed surgical resection of central nervous system germ cell tumors. Neurosurgery 2002; 50:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/64\">",
"      Kochi M, Itoyama Y, Shiraishi S, et al. Successful treatment of intracranial nongerminomatous malignant germ cell tumors by administering neoadjuvant chemotherapy and radiotherapy before excision of residual tumors. J Neurosurg 2003; 99:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/65\">",
"      Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer 1982; 50:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/66\">",
"      Finlay J, Kriegger M, Nasta A, et al. Treatment of primary CNS germinomatous germ cell tumors (GCT) with chemotherapy prior to reduced-dose ventricular field irradiation: The Children's Hospital Los Angeles Experience 2003-2007. J Neurooncol 2008; 10:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/67\">",
"      Rustin GJ, Newlands ES, Bagshawe KD, et al. Successful management of metastatic and primary germ cell tumors in the brain. Cancer 1986; 57:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/68\">",
"      Lee AC, Chan GC, Fung CF, et al. Paradoxical response of a pineal immature teratoma to combination chemotherapy. Med Pediatr Oncol 1995; 24:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/69\">",
"      O'Callaghan AM, Katapodis O, Ellison DW, et al. The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: a case report and review. Cancer 1997; 80:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/70\">",
"      Hanna A, Edan C, Heresbach N, et al. [Expanding mature pineal teratoma syndrome. Case report]. Neurochirurgie 2000; 46:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/71\">",
"      Yagi K, Kageji T, Nagahiro S, Horiguchi H. Growing teratoma syndrome in a patient with a non-germinomatous germ cell tumor in the neurohypophysis--case report. Neurol Med Chir (Tokyo) 2004; 44:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/72\">",
"      Kong DS, Nam DH, Lee JI, et al. Intracranial growing teratoma syndrome mimicking tumor relapse: a diagnostic dilemma. J Neurosurg Pediatr 2009; 3:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30105/abstract/73\">",
"      Kim CY, Choi JW, Lee JY, et al. Intracranial growing teratoma syndrome: clinical characteristics and treatment strategy. J Neurooncol 2011; 101:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5199 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30105=[""].join("\n");
var outline_f29_25_30105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Molecular biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H431567392\">",
"      - Pineal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H431567399\">",
"      - Suprasellar tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CSF cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Germinomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Craniospinal irradiation RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Whole ventricular RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Chemotherapy only",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Beta-HCG secreting germinomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nongerminomatous GCTs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Craniospinal irradiation in NGGCTs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Extent of surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Growing teratoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Recurrent NGGCTs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment of germinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment of NGGCTs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/29/8667\" title=\"table 1\">",
"      WHO IGCTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/11/14524\" title=\"table 2\">",
"      WHO GCTs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16714?source=related_link\">",
"      Pineal gland masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17894?source=related_link\">",
"      Sacrococcygeal germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_25_30106="Management of locally advanced unresectable esophageal cancer";
var content_f29_25_30106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of locally advanced unresectable esophageal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Dwight E Heron, MD, FACRO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Michael K Gibson, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/25/30106/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/25/30106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with unresectable or inoperable esophageal cancer is challenging and requires a multimodality approach. This is a heterogeneous group that includes patients with potentially resectable (T4a, (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    )) and unresectable (T4b) primary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/1\">",
"     1",
"    </a>",
"    ], poor surgical candidates, and those who refuse surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'TNM staging criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged progression-free survival (PFS) is possible in a few of these patients; however, palliation rather than cure of the cancer is the treatment goal for the majority, and quality of life (QOL) issues generally predominate. A major goal of therapy is restoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintaining the ability to swallow, managing pain and preventing bleeding.",
"   </p>",
"   <p>",
"    To achieve these goals, a variety of therapies may be used, including external beam radiation therapy (RT) with or without chemotherapy, esophageal dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stenting, photodynamic therapy (PDT), laser ablation, chemical ablation, and palliative surgery.",
"   </p>",
"   <p>",
"    Optimal palliation usually requires the integration of two or more of these modalities, either concurrently or sequentially. While combined modality therapy offers a small but real chance of prolonged PFS and potentially overall survival, improvement in QOL and sustained relief of dysphagia can be achieved in the majority of patients. However, the durability of symptom palliation is variable.",
"   </p>",
"   <p>",
"    This topic focuses on locoregional therapy for locally advanced, inoperable esophageal cancer. The roles of palliative surgery and RT without or with concurrent chemotherapy will be covered as well as an overview of endoscopic procedures for palliation of swallowing (dilation, stenting, PDT, and laser ablation). Other approaches to localized esophageal cancer and metastatic disease, as well as a more detailed discussion of endoscopic palliation, are provided in other topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link&amp;anchor=H5#H5\">",
"     \"Expandable stents in the treatment of esophageal obstruction\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GRADING OF DYSPHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia is a subjective term that encompasses any difficulty in swallowing food, liquids, or oral secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/2\">",
"     2",
"    </a>",
"    ]. Dysphagia can be caused by benign or malignant disorders of the oral cavity, oropharynx, or esophagus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the lack of standardization for grading the severity of dysphagia, published reports vary in how they quantify or characterize dysphagia. The Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) developed a grading scale for late effects of RT that helps standardize the evaluation of dysphagia (",
"    <a class=\"graphic graphic_table graphicRef70813 \" href=\"UTD.htm?6/28/6603\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/3\">",
"     3",
"    </a>",
"    ]. These criteria are especially useful for radiation-induced benign strictures. The NCI Common Terminology Criteria for Adverse Events (CTCAE) provide a separate grading scale for dysphagia and long-term",
"    <span class=\"nowrap\">",
"     stricture/stenosis",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for esophageal and esophagogastric junction (EGJ) cancer is used universally. Among the major changes between the 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/1\">",
"     1",
"    </a>",
"    ] and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/5\">",
"     5",
"    </a>",
"    ] editions were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of separate stage groupings for squamous cell cancers and adenocarcinomas (",
"      <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The inclusion of tumors at the esophagogastric junction (EGJ) and proximal 5 cm of the stomach that extend into the esophagus",
"     </li>",
"     <li>",
"      A reassignment of the stage groupings based upon T, N, and M criteria as well as tumor grade",
"     </li>",
"     <li>",
"      The subclassification of T4 disease into T4a (potentially resectable) and T4b (unresectable) disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Staging and evaluation for resectability requires endoscopic ultrasound (EUS) for T staging (focusing on the possibility of T4 disease), computed tomography (CT), and [18F]-2-deoxy-D-glucose positron emission tomography (FDG-PET), which is often integrated with CT",
"    <span class=\"nowrap\">",
"     (PET/CT).",
"    </span>",
"    For squamous cell carcinomas (SCC) located at or above the carina, bronchoscopy is indicated to rule out tracheoesophageal fistula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preoperative EUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locoregional tumor staging is accomplished with EUS, which uses a high frequency ultrasound transducer to provide detailed, radial images of the layers of the esophageal wall, esophageal masses, and extraesophageal tissues, including lymph nodes and other nearby structures. EUS is consistently better than CT for staging the primary and locoregional nodes, both by imaging suspicious nonpathologic-sized nodes and by guiding needle biopsies of suspicious areas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some limitations to the use of EUS for tumor staging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While EUS is accurate for discriminating T1 from T2 tumors, it is somewhat less accurate in discriminating T3 from T4 lesions, a relevant distinction for the surgeon contemplating resection with curative intent.",
"     </li>",
"     <li>",
"      The instrument cannot traverse a tumor-induced stenosis (which affects about 30 percent of patients). In such cases, the tumor may be understaged, because the entire lesion and the celiac axis are not seen [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/6\">",
"       6",
"      </a>",
"      ]. Pre-procedure endoscopic dilatation may permit accurate endosonographic staging by allowing the instrument to traverse the stenotic area [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessment of lymph nodes in the immediate vicinity of the tumor is restricted. These nodes often cannot be biopsied to confirm the presence of metastases, because the needle would have to traverse the tumor itself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tumors involving the upper two-thirds of the esophagus (at or above the carina) must undergo bronchoscopy (usually rigid bronchoscopy) to rule out fixation or invasion of the posterior membranous trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/8\">",
"     8",
"    </a>",
"    ]. Mucosal irregularities, thickening or indentation of the normally flat or slightly convex membranous wall of the trachea, fistula formation, bulging of the posterior membranous trachea or the left main stem bronchus, or direct tumor extension into the airway imply locally advanced unresectable tumor. Biopsies of these areas are mandatory to document tumor involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluation for distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for distant metastases is carried out with systemic imaging (CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET scanning), EUS (which may visualize liver metastases), and diagnostic laparoscopy. FDG-PET is the most useful test to rule out distant metastatic disease, which can be identified in approximately 20 percent of patients who appear to be free of metastases on CT and EUS. Integrated PET-CT is more sensitive than either CT or PET alone. These issues are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PET is not as useful to rule out brain metastases. Because of high basal uptake of FDG by normal brain tissues, the low signal-to-noise ratio of FDG-PET may result in false negative results. Patients who have locally advanced esophageal cancer and symptoms referable to the brain warrant a brain MRI to detect metastases. Brain imaging is not routinely performed in asymptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Criteria for unresectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although criteria vary according to institution and individual surgeon, the presence of any of the following is generally considered to preclude resection:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10737238\">",
"    <span class=\"h3\">",
"     Distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of peritoneal, lung, bone, adrenal, brain, or liver metastases, or extraregional lymph node spread (eg, paraaortic or mesenteric lymphadenopathy) precludes an attempt at resection.",
"   </p>",
"   <p>",
"    The finding of a malignant node in the celiac area remote from the primary tumor (eg, for a SCC in the upper or middle thoracic esophagus) was previously thought to be a sign of unresectability and considered metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/5\">",
"     5",
"    </a>",
"    ]. However, celiac nodal metastases are scored as regional nodal disease in the new 2010 edition of the TNM staging system, regardless of the primary tumor location or histology, and they no longer carry the connotation of distant metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, prognosis is poor in such cases, even if the primary tumor is located in the distal esophagus or EGJ [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one series, the two-year survival rate of patients with celiac node involvement who underwent surgery as a component of therapy was approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10737245\">",
"    <span class=\"h3\">",
"     Unresectable primary disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10737252\">",
"    <span class=\"h4\">",
"     Thoracic or abdominal esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the latest revision of the combined AJCC (American Joint Committee on",
"    <span class=\"nowrap\">",
"     Cancer)/UICC",
"    </span>",
"    (International Union Against Cancer) TNM staging criteria, unresectable T4 (T4b) primary disease includes invasion of the aorta, trachea, heart, great vessels, or the presence of a tracheoesophageal fistula (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"UTD.htm?13/38/13934\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"UTD.htm?4/24/4494\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/1\">",
"     1",
"    </a>",
"    ]. Invasion of the pleura, pericardium, or diaphragm is classified as T4a disease, and considered potentially resectable disease.",
"   </p>",
"   <p>",
"    A thorough evaluation of the airway is mandatory for all supracarinal esophageal cancers, including those involving the middle third of the esophagus (",
"    <a class=\"graphic graphic_figure graphicRef76958 \" href=\"UTD.htm?4/36/4678\">",
"     figure 1",
"    </a>",
"    ). Meticulous attention should be paid to the preservation or obliteration of fat planes between the esophagus and adjacent structures on chest CT. In general, preservation of fat planes implies no direct tumor invasion and suggests potential resectability.",
"   </p>",
"   <p>",
"    On the other hand, obliteration of the fat plane does not necessarily indicate direct tumor invasion and unresectability. In normal patients, fat may be absent between an esophageal carcinoma and the aorta, trachea, left main bronchus, or pericardium, thus complicating the differentiation between an abutting tumor and true invasion. Fat planes may also be absent in cachectic patients who do not have evidence of tumor invasion.",
"   </p>",
"   <p>",
"    If the tumor abuts the aorta with obliteration of the normal adventitial plane, there will likely be a positive radial margin, but this finding does not preclude exploration if there are no other findings to indicate unresectability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Invasion of the aorta (and thus, unresectable disease) is suggested by an arc of contact between the tumor and the aorta that is more than 90 degrees, although this is not absolute confirmation of an unresectable T4 tumor.",
"   </p>",
"   <p>",
"    There are selected patients with seemingly locally unresectable disease who might achieve a sufficient response from preoperative therapy to then undergo a potentially curative resection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/13\">",
"     13",
"    </a>",
"    ]. In this setting, initial staging laparoscopy is warranted, and restaging with",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    after chemoradiotherapy prior to planned esophagectomy is useful to detect interval metastases (which were found in 8 percent of such patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/14\">",
"     14",
"    </a>",
"    ]), and thus, avoid an unnecessary operation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Intraoperative staging'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H28\">",
"     'Post-chemoradiotherapy surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10737259\">",
"    <span class=\"h4\">",
"     Cervical esophageal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For tumors of the cervical esophagus (which extends from the hypopharynx to the sternal notch) (",
"    <a class=\"graphic graphic_figure graphicRef76958 \" href=\"UTD.htm?4/36/4678\">",
"     figure 1",
"    </a>",
"    ), infiltration into the prevertebral fascia or posterior larynx, invasion of the membranous trachea to the level of the carina, or significant bilateral encasement of major neurovascular structures precludes surgical resection. Regardless of apparent resectability, however, tumors of the cervical esophagus are rarely resected due to the resultant functional deficits and impairment of quality of life. They are more often treated as head and neck SCCs are. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Cervical tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intraoperative staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial staging evaluation, patients with locally advanced disease can be subdivided into those who have a reasonable expectation of undergoing a complete (R0) resection and those who do not. This distinction is not always easy, and considerable experience and judgment are needed. Sometimes intraoperative assessment is needed.",
"   </p>",
"   <p>",
"    For patients who appear to be potentially resectable, the following criteria may be used intraoperatively by the surgeon to ultimately determine resectability:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraoperative bronchoscopy or mediastinal exploration may demonstrate whether a margin-negative resection can be accomplished, particularly if the CT or EUS are equivocal. Resection should not be attempted if there is extensive involvement of the membranous trachea or pericardium or aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, resection would be considered palliative rather than curative if exploration of the abdomen revealed infiltration of the soft tissues around the aorta, celiac trunk, or distal stomach.",
"     </li>",
"     <li>",
"      At some institutions, all patients with distal esophageal adenocarcinomas and no clear evidence of distant metastases undergo a staging laparoscopy to rule out peritoneal carcinomatosis and occult metastatic disease. Laparoscopic staging may provide useful information that might spare patients from the unnecessary exploratory operations and palliative resections that were common in the past. However, there is no consensus as to the indications for diagnostic laparoscopy in this setting. Diagnostic laparoscopy is most often considered for patients with distal esophageal and EGJ adenocarcinomas, because intraperitoneal metastases are more common in this situation and notoriously difficult to diagnose noninvasively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H15#H15\">",
"       \"Diagnosis and staging of esophageal cancer\", section on 'Laparoscopy and thoracoscopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link&amp;anchor=H3443822#H3443822\">",
"       \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Diagnostic laparoscopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some situations where laparoscopy may be helpful are discussed in the following sections.",
"   </p>",
"   <p>",
"    The role of staging thoracoscopy is also not well defined. Exploratory thoracoscopy can exclude a clinical T4 (cT4) tumor from resectability, but to do so requires dissection of the primary tumor away from the adjacent structure presumed to be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Laparoscopy and thoracoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SURGICAL PALLIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative resection is usually not considered for patients with locally advanced disease and distant metastases due to their short life expectancy (usually less than six months). Palliative resection is also no longer considered a valid concept for patients with locally advanced nonmetastatic esophageal cancer. Perioperative morbidity and mortality rates are high, and the opportunity for potentially curative alternatives such as definitive chemoradiotherapy may be lost. Furthermore, although palliative resection can relieve dysphagia, restoration of the ability to swallow can now be accomplished successfully nonsurgically in the majority of patients and is most commonly achieved by the placement of an endoluminal stent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like palliative esophagectomy, surgical bypass provides limited benefit and is associated with substantial morbidity in patients with clearly unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/11,12,15-17\">",
"     11,12,15-17",
"    </a>",
"    ]. Although these palliative bypasses relieve symptoms, complication rates usually exceed 50 to 60 percent, and mortality rates are between 5 and 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ]. As a result, these procedures are now rarely attempted.",
"   </p>",
"   <p>",
"    Instead, the recommended treatment for inoperable patients with local tumor invasion of the airway or aorta, or extraregional abdominal metastases, is endoscopic therapy, stent placement, RT, or combined chemotherapy and radiation (see below). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic interventions may be appropriate for palliation of dysphagia in patients who have advanced esophageal cancer in the following settings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients for whom definitive management is planned, but who have severe dysphagia at presentation, requiring intervention prior to therapy",
"     </li>",
"     <li>",
"      Failure to achieve adequate palliation of dysphagia with initial therapy",
"     </li>",
"     <li>",
"      Recurrent dysphagia due to locoregional failure",
"     </li>",
"     <li>",
"      Recurrent dysphagia due to benign strictures in patients who are successfully treated with RT",
"     </li>",
"     <li>",
"      Patients are poor candidates for either chemotherapy or RT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several endoscopic approaches to providing palliation from malignant dysphagia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilation",
"     </li>",
"     <li>",
"      Laser therapy",
"     </li>",
"     <li>",
"      Endoscopic injection therapies",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection",
"     </li>",
"     <li>",
"      Photodynamic therapy",
"     </li>",
"     <li>",
"      Placement of a prosthetic self expanding plastic (SEPS) or metal stent (SEMS)",
"     </li>",
"     <li>",
"      Brachytherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stenting is preferred for patients with a malignant stricture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fistula. In the absence of a fistula, optimal therapy remains controversial. A systematic review of interventions for palliation of dysphagia associated with locally advanced esophageal cancer concluded that insertion of an SEMS is safe and provides rapid relief of dysphagia, while thermal and chemical ablative therapy provided comparable dysphagia palliation but with an increased requirement for reintervention and adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/18\">",
"     18",
"    </a>",
"    ]. Brachytherapy is a suitable alternative, which may be associated with improved survival and quality of life.",
"   </p>",
"   <p>",
"    Endoscopic approaches to palliation in esophageal cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link\">",
"     \"Expandable stents in the treatment of esophageal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RADIATION THERAPY (EBRT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, external beam RT played an important role in the management of unresectable esophageal cancer, both for palliation of dysphagia and for maintenance of long-term locoregional disease control. Although RT alone may successfully palliate dysphagia (see below), sustained remission and long-term survival are rarely achieved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series in which patients were treated with RT alone, three- to five-year survival rates were 1 and 2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an RTOG trial in which patients with localized esophageal cancer (mostly squamous cell cancers) were randomly assigned to combined modality therapy versus RT alone without planned surgery, all patients in the RT alone arm were dead by three years; in contrast, 27 percent of those undergoing chemoradiotherapy remained alive at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others report slightly better results from EBRT alone for inoperable esophageal SCC (10 to 15 percent alive at four years) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the use of RT alone may provide a small chance of long-term palliation, most experts consider that combined chemoradiotherapy provides superior palliation and the potential for long-term PFS. It is the preferred approach for patients who are suitably fit for combined therapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Combined modality therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Palliation of dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the minimal long-term survival benefit of EBRT alone, significant palliation of swallowing is noted in the majority, albeit for a variable period of time. In a series that examined the difference in food-passage scores before and after RT in 127 patients with esophageal cancer, dysphagia was improved and adequately palliated until death in 71 and 54 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the duration of benefit may be too short for patients who are expected to survive longer than three to six months. In a report of 103 patients who underwent RT alone (50 to 60 Gy), dysphagia was palliated for an average of three months in 89 percent of patients; only 14 percent had sustained relief of dysphagia for longer than 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications and disadvantages of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo RT are at risk for tracheoesophageal (TE) fistulas and postradiotherapy esophageal strictures which may be either benign or malignant, and may lead to recurrent dysphagia. The prevalence of malignant and nonmalignant postradiotherapy strictures was about equal in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/26\">",
"     26",
"    </a>",
"    ]. The majority of patients with benign strictures were successfully dilated and had a 12 month survival rate of 88 percent compared to 19 percent for those with malignant strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another major inconvenience is the time it takes to administer therapeutic EBRT (five to six weeks, which may represent a substantial portion of the patient's remaining lifespan).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     TE fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with esophageal cancer, a TE fistula may develop in the setting of a locally advanced tumor, or as a complication of EBRT or chemoradiotherapy. Combined modality therapy for patients who present with a TE fistula in the setting of locally advanced disease is addressed below (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Patients with a malignant fistula'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The incidence of a TE fistula during chemoradiotherapy was 6 percent in one series and accounted for one-half of all fistulas that developed in patients with esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/27\">",
"     27",
"    </a>",
"    ]. The others presented before the initiation of therapy; in this cohort, spontaneous closure of the fistula after completion of chemoradiotherapy was noted in 70 percent.",
"   </p>",
"   <p>",
"    Esophageal stenting is a risk factor for TE fistula, particularly in combination with RT. In a report of 208 patients who underwent stent placement with or without palliative RT for inoperable locally advanced esophageal cancer, 18 developed a TE fistula, 17 of whom had received RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of a TE fistula was higher among patients who received RT after stent placement compared to those who received it beforehand.",
"   </p>",
"   <p>",
"    For patients with persistent TE fistula after the completion of treatment, options for symptomatic management include airway stents, esophageal stents (",
"    <a class=\"graphic graphic_picture graphicRef60771 \" href=\"UTD.htm?28/7/28785\">",
"     picture 1",
"    </a>",
"    ), or surgery. In most cases, symptomatic treatment and closure of the fistula is achieved with stenting; dual stenting appears to work better than single prosthesis both for palliation and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link\">",
"     \"Expandable stents in the treatment of esophageal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatives to stenting include esophageal exclusion with cervical esophagostomy, gastrostomy, and placement of a jejunostomy feeding tube. Esophageal bypass is rarely needed. Palliative esophageal resection with repair of the fistula, tracheoesophageal reconstruction, or placement of a gastrostomy tube is not warranted because it is extremely complicated and is usually associated with high morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMBINED MODALITY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive chemoradiotherapy is the standard nonoperative treatment for unresectable, locoregional esophageal cancer. In many institutions, neoadjuvant chemoradiotherapy has emerged as the preferred option to upfront surgery for patients with potentially resectable disease. The results of trials that compare combined modality therapy (chemotherapy, RT, with or without surgery) versus surgery alone are discussed in detail elsewhere. The following sections will emphasize results of combined modality therapy in patients with inoperable nonmetastatic locoregionally advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cervical tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 5 and 6 percent of esophageal cancers arise in the cervical portion of the esophagus, which is 6 to 8 cm long and extends from the hypopharynx to the sternal notch (",
"    <a class=\"graphic graphic_figure graphicRef76958 \" href=\"UTD.htm?4/36/4678\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/30\">",
"     30",
"    </a>",
"    ]. Locally advanced disease is usually present at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical esophageal SCCs present a unique management challenge. Treatment is more closely related to SCC of the head and neck than to thoracic esophageal cancer. As an example, radical neck dissection is usually carried out as a component of multimodality therapy. Many series report combined outcomes for hypopharyngeal and cervical esophageal cancers.",
"   </p>",
"   <p>",
"    If surgery is performed, it usually requires removal of portions of the pharynx, the larynx, the thyroid gland, and portions of the proximal esophagus, or the entire esophagus (pharyngo-laryngo-esophagectomy [PLE]). This one-stage, three-phase operation requires cervical, abdominal and thoracic incisions and a permanent terminal tracheostomy. Restoration of GI tract continuity can be accomplished with a gastric pull-up and anastomosis to the pharynx. For tumors confined to the proximal portion of the cervical esophagus with a sufficient distal resection margin, alternatives for reconstruction include a free jejunal interposition graft or a deltopectoral or pectoralis major myocutaneous flap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=see_link&amp;anchor=H7377428#H7377428\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Cervical esophageal cancer resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although surgery may be considered for selected patients with earlier stage disease, RT combined with chemotherapy is preferred for patients with locally advanced disease, because survival is the same, and major morbidity is avoided in most [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/30,32-38\">",
"     30,32-38",
"    </a>",
"    ]. In one series of 32 patients treated with chemoradiotherapy and salvage surgery, the ten-year survival rate was 27 percent, and 15 of 32 successfully preserved their larynx [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Conventional chemoradiotherapy for thoracic and abdominal esophageal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many randomized controlled trials have compared chemoradiotherapy to RT alone for definitive therapy of esophageal cancer. Some show a significant survival advantage for the addition of chemotherapy to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/21,22,24\">",
"     21,22,24",
"    </a>",
"    ], but many do not. Most of these studies were flawed because of suboptimal doses of RT or chemotherapy, or the sequential rather than concurrent delivery of chemotherapy and RT. Sequential administration is now recognized as inferior to concurrent use of chemotherapy and RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H7#H7\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Definitive chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     RTOG 85-01",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only randomized trial that used adequate RT doses and modern concurrent chemotherapy, the landmark RTOG 85-01 trial, demonstrated that the addition of concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy to conventional fractionation RT provided a significant survival benefit compared to treatment with RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients with locoregional (T1-3,N0-1,M0) esophageal cancer were randomly assigned to chemoradiotherapy (two cycles of infusional 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, days 1 to 4, weeks 1 and 5] plus cisplatin [75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1 of weeks 1 and 5] plus RT [50.4 Gy in 25 fractions over five weeks]), or RT alone (64 Gy). Chemoradiotherapy was associated with a significantly better median survival (14 versus 9 months) and five year survival (27 versus 0 percent). These data resulted in the widespread adoption of chemoradiotherapy rather than RT alone for definitive nonoperative treatment of locoregional esophageal cancer.",
"   </p>",
"   <p>",
"    Patients with T4 disease were not included in this study. Because the inclusion criteria did not require surgical unresectability, the study group likely represents, on average, a prognostically more favorable population than those with unresectable locally advanced disease. Furthermore, 85 percent of the study group had SCC. Nevertheless, these data are widely considered to provide support for the superiority of chemoradiotherapy over RT in patients with unresectable locally advanced esophageal SCC or adenocarcinoma. Guidelines from the National Comprehensive Cancer Network (NCCN) for treatment of medically fit patients with unresectable T4 or IVA disease suggest concurrent chemoradiotherapy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Relief of dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined chemoradiotherapy provides long-lasting palliation of dysphagia in most patients with unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. One report described posttreatment swallowing function in 120 patients who were treated with different combination regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/40\">",
"     40",
"    </a>",
"    ]. The majority of evaluable patients (88 percent) noted improvement in dysphagia within an average of two weeks. Benefit was maximal by four weeks in 86 percent of responding patients. At this time point, all but two could swallow at least soft or solid food without dysphagia. Two-thirds of the patients treated with palliative intent had no significant dysphagia until death or last follow-up examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Patients with a malignant fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of a tracheoesophageal (TE) fistula is a serious complication that carries a dismal prognosis. The majority of these patients have recurrent disease or develop this complication during chemoradiotherapy; most are managed with an endoscopically-placed esophageal stent. However, reintervention is necessary in up to 40 percent of cases, and stenting is generally not feasible for lesions that are close to the GE junction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link&amp;anchor=H5#H5\">",
"     \"Expandable stents in the treatment of esophageal obstruction\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a malignant esophageal fistula in patients with locoregionally advanced esophageal cancer was historically considered a relative contraindication for RT or chemoradiotherapy because of the high rate of perforation seen in patients treated for T4 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Complications and disadvantages of RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, at least some data support the view that selected patients who have a previously unirradiated T4 lesion with a malignant fistula can be safely treated with chemoradiotherapy, with some achieving at least transient closure of the fistula and occasionally long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/9,45\">",
"     9,45",
"    </a>",
"    ]. Toxicity may be prominent, and most patients fail to achieve long-term local control. The best way to select those patients who might benefit from chemoradiotherapy versus surgery or placement of airway or esophageal stents is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy with concurrent chemotherapy is a standard approach for patients with locally advanced unresectable or inoperable thoracic esophageal cancer (including those with a malignant TE fistula) who are medically able to tolerate chemotherapy. Most patients achieve sustained palliation of dysphagia, and a few will have the opportunity for long-term progression-free survival. The role of postchemoradiotherapy surgery is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment intensification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Radiation Therapy Oncology Group (RTOG) protocol 85-10 clearly demonstrated that patients with locally advanced esophageal cancer can be cured without surgery, the local failure rate (persistent and recurrent disease) of approximately 45 percent in patients treated with definitive chemoradiotherapy (as has been seen in other trials as well [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]) leaves much room for improvement.",
"   </p>",
"   <p>",
"    A number of modifications of the chemoradiotherapy regimen used in RTOG 85-10 have been explored in an attempt to improve outcomes in patients with unresectable or inoperable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Radiation therapy (RT) dose intensification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US Intergroup trial 0123, high dose RT (64.8 Gy) was compared to the previous standard of 50.4 Gy, both administered with concurrent chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus infusional 5-FU) in 236 patients with clinical stage T1-4 (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    ) Nx M0 esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/46\">",
"     46",
"    </a>",
"    ]. Two additional chemotherapy courses were repeated four weeks after the completion of RT. The trial was closed early because there was no demonstrable survival or local control advantage from higher dose RT. Furthermore, there was a higher rate of toxic deaths (9 versus 2 percent) with the higher RT dose. One- and two-year survival rates were 66 and 40 percent, respectively.",
"   </p>",
"   <p>",
"    Accelerated fractionation RT was evaluated in a nonrandomized trial.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    (360",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV day 1 of each treatment cycle) was substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and combined with concurrent 5-FU (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for five days during weeks 1 and 5, and 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for five days during weeks 9 and 13), and accelerated split-course RT (2 Gy, twice daily during weeks 1 and 5, for a total dose of 40 Gy) in 27 patients with locally advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/48\">",
"     48",
"    </a>",
"    ]. Ten had disease limited to the esophagus. Although local control was excellent, with only one patient having disease progression in the radiation treatment volume, the median survival was only six months.",
"   </p>",
"   <p>",
"    Thus, neither of these approaches can be recommended over standard fractionation RT (50.4 Gy total dose in daily 1.8 to 2 Gy fractions).",
"   </p>",
"   <p>",
"    Another approach to RT dose intensification is the addition of brachytherapy to external beam RT and chemotherapy. No randomized trials have compared this approach to chemoradiotherapy alone. The results of non-randomized, non-prospective trials have been mixed, with some suggesting encouraging tumor control and survival from the addition of brachytherapy to external beam RT and chemotherapy, and others prohibitive toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Chemotherapy intensification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Others have explored the use of novel combinations, targeted agents or alternative radiation sensitizers (eg, taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) during RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/51-58\">",
"     51-58",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Although results from phase II trials are encouraging, phase III trials are required before it can be concluded that any of these approaches are better than conventional concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-FU. A preliminary report of one such trial involving 267 patients with technically unresectable cancer, a surgical contraindication, or refusal of surgery reported no progression-free or overall survival benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (the FOLFOX regimen) compared to cisplatin and FU during chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and other approaches to chemotherapy intensification are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Induction plus concurrent chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 75 percent of patients diagnosed with locally advanced disease will ultimately develop distant metastases, providing the rationale for studying induction systemic chemotherapy prior to chemoradiotherapy. While phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    studies have shown that this approach is feasible and provides significant relief of dysphagia in up to 90 percent of patients, no trials have compared this approach to concurrent chemoradiotherapy alone. Most of the trials evaluating this approach have been conducted in patients with locally advanced but potentially resectable disease and are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two of the only trials to include patients with T4 disease are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial included 172 patients with T3-4, N0-1, M0 SCC (29 with endoscopic ultrasound (EUS)-staged T4 disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/47\">",
"       47",
"      </a>",
"      ]. The treatment groups were induction chemotherapy (three 21-day courses of bolus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      on days 1 to 3) followed by chemoradiotherapy (40 Gy RT with concurrent cisplatin and etoposide on days 2 through 8) and then surgery, or the same induction chemotherapy followed by chemoradiotherapy (RT dose at least 65 Gy) without surgery.",
"      <br/>",
"      <br/>",
"      Only 62 of the 86 patients in the surgery arm underwent surgery, and this number was not broken down according to the initial EUS T stage. Overall survival was similar in both groups, although two-year progression-free survival significantly favored the surgery arm (64 versus 41 percent). Treatment-related mortality was also significantly higher in this group (13 versus 4 percent). Tumor response to induction chemotherapy identified a prognostically favorable group within both treatment arms. The major criticism of this study was its small size and the relatively low RT dose in the surgery arm.",
"     </li>",
"     <li>",
"      The RTOG conducted a multi-institutional phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiotherapy in patients with nonmetastatic esophageal cancer (25 SCC, 47 adenocarcinoma) who were technically unresectable or",
"      <span class=\"nowrap\">",
"       unwilling/medically",
"      </span>",
"      unfit for surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/60\">",
"       60",
"      </a>",
"      ]. One group received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      -based induction chemotherapy (5-FU,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      followed by RT [50.4 Gy] concurrent with paclitaxel and 5-FU, arm A), while the other received non-fluoropyrimidine-based therapy (induction paclitaxel plus cisplatin followed by the same regimen concurrent with 50.4 Gy RT, arm B).",
"      <br/>",
"      <br/>",
"      Treatment-related morbidity was prominent in both groups; grade 3 toxicity developed in 54 and 40 percent of patients in arms A and B, respectively, while the corresponding rates of grade 4 toxicity were 27 and 40 percent. The rate of gastrointestinal grade 3 or 4 toxicity was similar in both groups (54 and 60 percent in arms A and B). There was one treatment-related death in arm A and two in arm B.",
"      <br/>",
"      <br/>",
"      At one and two years, 76 and 56 percent of the patients in arm A were alive, respectively, while the corresponding rates in arm B were 69 and 37 percent, respectively. The authors concluded that both approaches were toxic, and neither was sufficiently superior to historical results from INT 0123 (RTOG 94-05, one- and two-year survival or 66 and 40 percent in the standard RT dose arm) to justify their selection over standard cisplatin and 5-FU-based chemoradiotherapy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Radiation therapy (RT) dose intensification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it remains uncertain whether induction chemotherapy followed by concurrent chemoradiotherapy is superior to concurrent chemoradiotherapy alone for locally advanced esophageal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite intense efforts to improve on the results of RTOG 85-01, there are no other published regimens with clear superiority. Thus, if combined modality treatment is used, we use infusional 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, days 1 to 4 and 29 to 32) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    on days 1 and 29) plus EBRT (at least 50.4 Gy, concurrent with chemotherapy cycles 1 and 2) as was used in INT 0123 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Post-chemoradiotherapy surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of surgery following chemoradiotherapy among patients who present with locoregionally advanced esophageal cancer is an area of major controversy, even among those who present with potentially resectable disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H18#H18\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Necessity for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The key question for locally advanced unresectable or borderline resectable disease is whether neoadjuvant concurrent chemoradiotherapy can successfully downstage these patients to the point where they are potentially resectable. There are no trials that included patients with initially unresectable or borderline resectable disease. The only two randomized trials to address the benefit of postchemoradiotherapy surgery were conducted predominantly in patients with T3, N0-1 M0 squamous cell cancer (SCC), and both concluded that definitive chemoradiotherapy alone and chemoradiotherapy followed by surgery were equivalent in terms of two-year survival and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/47,61\">",
"     47,61",
"    </a>",
"    ]. Chemoradiotherapy alone, however, was associated with more local failures (40 to 50 percent) and a greater need for later endoscopic intervention for relief of dysphagia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H18#H18\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Necessity for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data have led some to conclude that definitive chemoradiotherapy is a reasonable option for patients with locoregionally advanced potentially resectable esophageal SCC who respond to initial therapy, although others disagree [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/62\">",
"     62",
"    </a>",
"    ]. The role of nonoperative treatment for adenocarcinomas remains poorly defined. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H18#H18\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Necessity for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Salvage esophagectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of a survival benefit from post-chemoradiotherapy surgery in patients with T3N0-1 esophageal cancer and the high local failure rates for chemoradiotherapy alone have led some to question whether post-chemoradiotherapy surgery could be selectively applied to patients who fail to respond or who recur after completing chemoradiotherapy alone. While long-term disease control has been achieved in a few patients (three-year survival rate 17 percent in one retrospective series of 46 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/63\">",
"     63",
"    </a>",
"    ]), there is little doubt that salvage esophagectomy is a more morbid operation than either primary esophagectomy or planned esophagectomy after neoadjuvant chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/63-71\">",
"     63-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The feasibility of salvage esophagectomy for persistent or recurrent disease following definitive chemoradiotherapy relates to two major issues: meticulous selection of candidates who are appropriate for salvage surgery (true local failures without metastatic disease) and experienced surgical skills in performing esophagectomy with measured and acceptable operative mortality.",
"   </p>",
"   <p>",
"    A major problem is the difficulty in diagnosing recurrent or persistent local disease. In contrast to the primary diagnosis of esophageal cancer, which is usually straightforward, EUS and CT are of limited utility for assessing locoregional therapeutic response; furthermore, endoscopic biopsies are sometimes negative despite the presence of viable tumor in deeper layers of the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/14\">",
"     14",
"    </a>",
"    ]. PET-CT may offer some advantages over conventional anatomic imaging; however, it too suffers from false positive and false negative results in patients with prior interventions, such as stent placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'EUS restaging after neoadjuvant chemoradiotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'PET restaging after initial induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A persistent stricture may be the only clue that malignant disease is present; confirmation is often difficult, but essential if salvage esophagectomy is being considered. A lack of tumor in the resected esophagectomy specimen represents a diagnostic failure and a particularly difficult situation should the patient die (disease-free) after surgery. Conclusive evidence of a local failure on a biopsy specimen and absence of metastases (distant failure) on a restaging PET scan should be obtained before embarking on salvage esophagectomy for locally recurrent disease.",
"   </p>",
"   <p>",
"    A locoregional failure following chemoradiotherapy may manifest as persistent disease at the completion of the planned definitive therapy (primary failure) or recurrent disease months later (secondary failure). Although surgery may be easier to perform in the setting of a primary failure, these patients are chemoradiotherapy non-responders, and their anticipated survival is poor. As a group, they are more likely to die from metastatic than locoregionally-recurrent disease. On the other hand, a carefully selected patient with a late recurrence may have a better cancer prognosis, but the potential for long-term survival must be balanced against the technical difficulty and greater morbidity of salvage esophagectomy in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage esophagectomy is a feasible therapeutic option for carefully selected patients who have recurrent disease following definitive chemoradiotherapy. Although there is no consensus as to which patients are appropriate candidates, we typically reserve salvage esophagectomy for patients with early stage recurrent disease (ie, node-negative, T1-2 disease) (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    ). Surgery should only be attempted if a complete (R0) resection is technically feasible.",
"   </p>",
"   <p>",
"    We generally do not pursue salvage surgery for patients with disease persistence after definitive chemoradiotherapy. Distant metastatic disease is the cause of death in the majority of such patients and esophagectomy is unlikely to be of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     BRACHYTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy permits treatment of a localized area of the esophagus to high radiation doses with relative sparing of surrounding structures. This technique may be used alone or in combination with external beam RT with or without chemotherapy. Brachytherapy should be considered an alternative to stent placement for palliation of dysphagia, particularly when the extent of extraluminal disease is limited and long-term palliation is likely. Although stenting has the advantage of palliating dysphagia immediately, the palliative effect of brachytherapy is frequently more durable.",
"   </p>",
"   <p>",
"    Brachytherapy involves intraluminal placement of a radioactive source into the esophagus with a nasogastric applicator. As a general rule, the diameter of the applicator should be 0.6 to 1.0 cm. Narrower applicators may deliver significantly higher doses to the mucosa resulting in significant acute and late treatment-related toxicities; larger catheters pose the risk of abrasion, perforation, or combination thereof. The dose of radiation is generally prescribed to a site 1 cm from the midsource or midwell position. An area covering 1 to 2 cm proximal and distal to the lesion is treated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brachytherapy can be administered by two general methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose rate brachytherapy (LDRB)",
"     </li>",
"     <li>",
"      High-dose rate brachytherapy (HDRB)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Modern HDRB equipment delivers radiation much faster than 0.2",
"    <span class=\"nowrap\">",
"     Gy/minute,",
"    </span>",
"    permitting the delivery of a planned dose within minutes compared with LDR sources, which require many hours or days. Since HDRB delivers a high dose of RT in a short period of time, fractionation is necessary; typically two to four fractions are administered for treatment of esophageal cancer.",
"   </p>",
"   <p>",
"    Brachytherapy alone can provide successful long-term palliation of dysphagia in patients with unresectable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/73-77\">",
"     73-77",
"    </a>",
"    ]. In a trial in which 209 patients with obstruction from esophageal or gastroesophageal junction tumors were randomly assigned to brachytherapy alone (12 Gy), or endoscopic placement of a metal stent, the stented group had more rapid improvement within 30 days of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/76\">",
"     76",
"    </a>",
"    ]. However, at later time points, brachytherapy was associated with significantly lower dysphagia severity scores and a significantly greater number of days with almost no dysphagia (115 versus 82 days). The brachytherapy group also had a significantly lower complication rate, as well as better quality of life scores, and they were no more likely to require retreatment for recurrent or persistent dysphagia than the stented group.",
"   </p>",
"   <p>",
"    The addition of a brachytherapy boost to external beam RT may improve outcomes over RT alone. The combination of chemoradiotherapy with a brachytherapy boost has been investigated in patients ineligible for surgical resection. However, randomized trials comparing this approach to chemoradiotherapy alone are not currently available, and the results of uncontrolled trials are mixed.",
"   </p>",
"   <p>",
"    While encouraging results are reported in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/78-81\">",
"     78-81",
"    </a>",
"    ], a nonrandomized, prospective RTOG trial of concurrent chemotherapy during both external beam RT and brachytherapy concluded that this combination was excessively toxic and not likely to enhance survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/82\">",
"     82",
"    </a>",
"    ]. Treatment consisted of external beam RT (50 Gy), a brachytherapy boost (20 Gy LDRB boost or 15 Gy HDRB boost delivered in three fractions), and chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) and infusional 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for 96 hours), given during weeks 1, 5, 8, and 11. The HDRB dose was later reduced to 10 Gy after an interim analysis suggested high levels of treatment-related toxicity. There was a 34 percent incidence of severe toxicity or death, and the median survival was only 11 months, a value which seems comparable to prior reports of concurrent external beam RT and chemotherapy given without brachytherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of brachytherapy (either LDRB or HDRB) in the treatment of unresectable esophageal cancer remains to be defined. Consensus guidelines for brachytherapy in the treatment of esophageal cancer from the American Brachytherapy Society are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef73664 graphicRef80000 \" href=\"UTD.htm?27/15/27901\">",
"     table 5A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/72\">",
"     72",
"    </a>",
"    ]. However:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In our view, brachytherapy can successfully palliate symptoms but as monotherapy, its use should be restricted to patients with a short life expectancy (less than six months). However, for patients who are expected to live less than three months, short-term palliation of swallowing may be better achieved with endoscopic stent placement. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endoscopic interventions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"       \"Endoscopic palliation of esophageal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link&amp;anchor=H5#H5\">",
"       \"Expandable stents in the treatment of esophageal obstruction\", section on 'Efficacy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A simple prognostic score to identify patients with a poor prognosis in whom stent placement may be preferable to brachytherapy has been developed [",
"      <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/83\">",
"       83",
"      </a>",
"      ]. However, this prognostic model has not been independently validated, and further study, particularly of long-term outcomes, is needed.",
"     </li>",
"     <li>",
"      Brachytherapy should be used with extreme caution in the setting of a local recurrence after prior chemoradiotherapy because of the risk of fistula formation.",
"     </li>",
"     <li>",
"      When used as a boost following concomitant chemotherapy and external beam radiation, brachytherapy may improve locoregional disease control. Given the toxicities reported in the RTOG and other single institutional trials, we recommend that chemotherapy not be administered concurrently with brachytherapy in the treatment of primary or recurrent esophageal cancers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally advanced, unresectable or inoperable esophageal cancer is incurable in the majority of patients. A major goal of treatment is improvement in quality of life by restoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintaining the ability to swallow and thus sustain adequate nutrition. For patients with metastatic disease, systemic chemotherapy is appropriate, and responders may have prolonged dysphagia-free periods. However, many patients require some form of local therapy to sustain locoregional control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, for patients with nonmetastatic locally unresectable or inoperable disease, combined modality therapy offers a small but real chance of sustained disease control and long-term survival. Furthermore, improvement in quality of life and prolonged relief of dysphagia are achieved in the majority of patients. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial staging evaluation should include an assessment of locoregional extent and possible distant spread (metastasis) (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Staging evaluation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CT of the chest and abdomen",
"     </li>",
"     <li>",
"      Endoscopic ultrasound (EUS)",
"     </li>",
"     <li>",
"      PET scan with integrated CT",
"      <span class=\"nowrap\">",
"       (PET/CT)",
"      </span>",
"     </li>",
"     <li>",
"      Rigid bronchoscopy for patients with supracarinal primary tumors, including those involving the middle third of the esophagus",
"     </li>",
"     <li>",
"      CT or MRI of the brain for patients who have symptoms referable to the central nervous system",
"     </li>",
"     <li>",
"      For patients who appear to be free of distant metastases, surgical staging with laparoscopy may be carried out for distal esophageal tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the finding of unresectable T4b disease (involving the aorta, trachea, vertebral body, heart, or great vessels, (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/1\">",
"     1",
"    </a>",
"    ]) or the presence of a tracheoesophageal fistula, or distant metastases precludes curative surgical resection. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Criteria for unresectability'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    For inoperable or unresectable esophageal squamous cell or adenocarcinoma, we recommend concurrent chemoradiotherapy rather than radiation therapy (RT) alone for patients who are able to tolerate this approach and who have an estimated life expectancy of greater than a few weeks (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Combined modality therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the optimal regimen has not been established, we prefer the concurrent chemoradiotherapy regimen as was used in RTOG 85-01 and the US Intergroup 0123 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/25/30106/abstract/22,46\">",
"     22,46",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H19\">",
"     'RTOG 85-01'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infusional 5-FU 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for 96 hours during weeks 1 and 5 of external beam radiation therapy (EBRT)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      on day 1, during weeks 1 and 5 of EBRT",
"     </li>",
"     <li>",
"      EBRT (50.4 Gy in daily 1.8 Gy fractions, given concurrently with cycles 1 and 2 of chemotherapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another option is the chemoradiotherapy regimen as used in the preoperative Dutch CROSS trial, weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    concurrent with RT (",
"    <a class=\"graphic graphic_table graphicRef68266 \" href=\"UTD.htm?2/49/2846\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link&amp;anchor=H4965589#H4965589\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'CROSS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The great majority of patients will not benefit from esophagectomy after chemoradiotherapy; however, selected patients with initially unresectable or borderline resectable disease (ie, limited T4) might achieve a sufficient response from preoperative chemoradiotherapy to then be able to undergo a potentially curative resection. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Post-chemoradiotherapy surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who undergo definitive chemoradiotherapy, salvage esophagectomy may be a feasible therapeutic option for carefully selected patients with small volume recurrent disease. The decision to pursue salvage esophagectomy must be made on a case by case basis. The best candidates for this approach are those who have early stage (ie, node-negative, T1-2 tumors (",
"    <a class=\"graphic graphic_table graphicRef58757 \" href=\"UTD.htm?4/35/4668\">",
"     table 1",
"    </a>",
"    )) recurrent rather than persistent disease. Definitive pathologic evidence of local failure and the absence of metastatic disease (using integrated",
"    <span class=\"nowrap\">",
"     PET/CT,",
"    </span>",
"    and laparoscopy for distal adenocarcinomas) should be clearly established prior to salvage esophagectomy. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Salvage esophagectomy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Evaluation for distant metastases'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who are unable to tolerate initial chemoradiotherapy or who have a short estimated life expectancy, we suggest alternative approaches to palliation of swallowing, such as brachytherapy or endoscopic therapy rather than concurrent chemoradiotherapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Brachytherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Endoscopic interventions (dilation, placement of an endoluminal stent, laser, and photodynamic therapy) are appropriate for palliation of dysphagia in the following settings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link&amp;anchor=H5#H5\">",
"     \"Expandable stents in the treatment of esophageal obstruction\", section on 'Efficacy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients for whom definitive management with chemoradiotherapy is planned, but who have severe dysphagia at presentation, requiring intervention prior to therapy",
"     </li>",
"     <li>",
"      A failure to achieve adequate palliation of dysphagia with initial therapy",
"     </li>",
"     <li>",
"      Recurrent dysphagia due to locoregional failure",
"     </li>",
"     <li>",
"      Recurrent dysphagia due to benign strictures in patients who are successfully treated with RT",
"     </li>",
"     <li>",
"      Patients who are poor candidates for either chemotherapy or radiation therapy",
"     </li>",
"     <li>",
"      Dysphagia associated with a tracheoesophageal fistula",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/2\">",
"      Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/3\">",
"      Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995; 31:1213.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03 available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 28, 2011).",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 6th, Greene FL, Page DL, Fleming ID, et al (Eds), Springer Verlag, New York 2001. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/6\">",
"      Mallery S, Van Dam J. Increased rate of complete EUS staging of patients with esophageal cancer using the nonoptical, wire-guided echoendoscope. Gastrointest Endosc 1999; 50:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/7\">",
"      Wallace MB, Hawes RH, Sahai AV, et al. Dilation of malignant esophageal stenosis to allow EUS guided fine-needle aspiration: safety and effect on patient management. Gastrointest Endosc 2000; 51:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/8\">",
"      Riedel M, Hauck RW, Stein HJ, et al. Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study. Chest 1998; 113:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/9\">",
"      Koike R, Nishimura Y, Nakamatsu K, et al. Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. Int J Radiat Oncol Biol Phys 2008; 70:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/10\">",
"      Eloubeidi MA, Wallace MB, Hoffman BJ, et al. Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg 2001; 72:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/11\">",
"      Bolton JS, Fuhrman GM, Richardson WS. Esophageal resection for cancer. Surg Clin North Am 1998; 78:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/12\">",
"      Mannell A, Becker PJ, Nissenbaum M. Bypass surgery for unresectable oesophageal cancer: early and late results in 124 cases. Br J Surg 1988; 75:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/13\">",
"      Forshaw MJ, Gossage JA, Chrystal K, et al. Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction. Eur J Surg Oncol 2006; 32:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/14\">",
"      Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007; 109:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/15\">",
"      Segalin A, Little AG, Ruol A, et al. Surgical and endoscopic palliation of esophageal carcinoma. Ann Thorac Surg 1989; 48:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/16\">",
"      Orringer MB. Substernal gastric bypass of the excluded esophagus--results of an ill-advised operation. Surgery 1984; 96:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/17\">",
"      Hirai T, Yamashita Y, Mukaida H, et al. Bypass operation for advanced esophageal cancer--an analysis of 93 cases. Jpn J Surg 1989; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/18\">",
"      Sreedharan A, Harris K, Crellin A, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev 2009; :CD005048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/19\">",
"      van Andel JG, Dees J, Dijkhuis CM, et al. Carcinoma of the esophagus: results of treatment. Ann Surg 1979; 190:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/20\">",
"      Petrovich Z, Langholz B, Formenti S, et al. Management of carcinoma of the esophagus: the role of radiotherapy. Am J Clin Oncol 1991; 14:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/21\">",
"      Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/22\">",
"      al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/23\">",
"      Caspers RJ, Welvaart K, Verkes RJ, et al. The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. Radiother Oncol 1988; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/24\">",
"      Wobbes T, Baron B, Paillot B, et al. Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. Eur J Cancer 2001; 37:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/25\">",
"      Wara WM, Mauch PM, Thomas AN, Phillips TL. Palliation for carcinoma of the esophagus. Radiology 1976; 121:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/26\">",
"      O'Rourke IC, Tiver K, Bull C, et al. Swallowing performance after radiation therapy for carcinoma of the esophagus. Cancer 1988; 61:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/27\">",
"      Muto M, Ohtsu A, Miyamoto S, et al. Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae. Cancer 1999; 86:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/28\">",
"      Park JY, Shin JH, Song HY, et al. Airway complications after covered stent placement for malignant esophageal stricture: special reference to radiation therapy. AJR Am J Roentgenol 2012; 198:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/29\">",
"      van den Bongard HJ, Boot H, Baas P, Taal BG. The role of parallel stent insertion in patients with esophagorespiratory fistulas. Gastrointest Endosc 2002; 55:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/30\">",
"      Mendenhall WM, Sombeck MD, Parsons JT, et al. Management of Cervical Esophageal Carcinoma. Semin Radiat Oncol 1994; 4:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/31\">",
"      Collin CF, Spiro RH. Carcinoma of the cervical esophagus: changing therapeutic trends. Am J Surg 1984; 148:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/32\">",
"      Bidoli P, Bajetta E, Stani SC, et al. Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 2002; 94:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/33\">",
"      Wang HW, Chu PY, Kuo KT, et al. A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol 2006; 93:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/34\">",
"      Jones AS, Roland NJ, Hamilton J, et al. Malignant tumours of the cervical oesophagus. Clin Otolaryngol Allied Sci 1996; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/35\">",
"      Stuschke M, Stahl M, Wilke H, et al. Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the cervical oesophagus. Oncology 1999; 57:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/36\">",
"      Burmeister BH, Dickie G, Smithers BM, et al. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 2000; 126:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/37\">",
"      Huang SH, Lockwood G, Brierley J, et al. Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. Int J Radiat Oncol Biol Phys 2008; 71:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/38\">",
"      Tong DK, Law S, Kwong DL, et al. Current management of cervical esophageal cancer. World J Surg 2011; 35:600.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/40\">",
"      Coia LR, Soffen EM, Schultheiss TE, et al. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 1993; 71:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/41\">",
"      Gill PG, Denham JW, Jamieson GG, et al. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . J Clin Oncol 1992; 10:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/42\">",
"      Wong SK, Chiu PW, Leung SF, et al. Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study. Ann Surg Oncol 2008; 15:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/43\">",
"      Ikeda E, Kojima T, Kaneko K, et al. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 2011; 41:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/44\">",
"      Ishida K, Iizuka T, Ando N, Ide H. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial. Jpn J Clin Oncol 1996; 26:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/45\">",
"      Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/46\">",
"      Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/47\">",
"      Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/48\">",
"      Urba SG, Turrisi AT 3rd. Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. Cancer 1995; 75:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/49\">",
"      Chiarion-Sileni V, Corti L, Ruol A, et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 2007; 96:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/50\">",
"      Ishikawa H, Sakurai H, Tamaki Y, et al. Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy. J Gastroenterol Hepatol 2006; 21:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/51\">",
"      Blanke CD, Choy H, Teng M, et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 1999; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/52\">",
"      Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000; 18:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/53\">",
"      Kim DW, Blanke CD, Wu H, et al. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2007; 67:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/54\">",
"      Chiarion-Sileni V, Innocente R, Cavina R, et al. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009; 63:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/55\">",
"      Ruppert BN, Watkins JM, Shirai K, et al. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010; 33:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/56\">",
"      Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Med Oncol 2012; 29:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/57\">",
"      Conroy T, Yatagh&egrave;ne Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010; 103:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/58\">",
"      Tomblyn MB, Goldman BH, Thomas CR Jr, et al. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol 2012; 7:906.",
"     </a>",
"    </li>",
"    <li>",
"     Conroy T, Galais MP, Raoul JL, et al. Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX of cisplatin and fluorouracil in esophageal cancer(EC): final results of the PRODIGE 5/ACCORD 17 trial. J Clin Oncol 30, 2012 (suppl; abstr LBA4003). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=93448 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/60\">",
"      Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008; 26:4551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/61\">",
"      Bedenne L, Michel P, Bouch&eacute; O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/62\">",
"      Morita M, Toh Y, Saeki H, et al. Clinical significance of chemoradiotherapy and surgical resection for cT4 esophageal cancer. Anticancer Res 2012; 32:3275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/63\">",
"      Nishimura M, Daiko H, Yoshida J, Nagai K. Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2007; 55:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/64\">",
"      Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002; 123:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/65\">",
"      Borghesi S, Hawkins MA, Tait D. Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol) 2008; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/66\">",
"      Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 2007; 94:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/67\">",
"      Piessen G, Briez N, Triboulet JP, Mariette C. Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery? Ann Surg Oncol 2007; 14:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/68\">",
"      D'Journo XB, Michelet P, Dahan L, et al. Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg 2008; 33:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/69\">",
"      Urschel JD, Ashiku S, Thurer R, Sellke FW. Salvage or planned esophagectomy after chemoradiation therapy for locally advanced esophageal cancer--a review. Dis Esophagus 2003; 16:60.",
"     </a>",
"    </li>",
"    <li>",
"     Hofstetter WL, Maru DM, Correa A, et al. Salvage resection for esophageal adenocarcinoma after failed definitive chemoradiation (abstract). Data presented at the 2009 ASCO Gastrointestinal Cancer Symposium, San Francisco, CA, January 16, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/71\">",
"      Miyata H, Yamasaki M, Takiguchi S, et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 2009; 100:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/72\">",
"      Gaspar LE, Nag S, Herskovic A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys 1997; 38:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/73\">",
"      Fleischman EH, Kagan AR, Bellotti JE, et al. Effective palliation for inoperable esophageal cancer using intensive intracavitary radiation. J Surg Oncol 1990; 44:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/74\">",
"      Jager JJ, Pannebakker M, Rijken J, et al. Palliation in esophageal cancer with a single session of intraluminal irradiation. Radiother Oncol 1992; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/75\">",
"      Sur RK, Levin CV, Donde B, et al. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys 2002; 53:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/76\">",
"      Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/77\">",
"      Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005; 18:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/78\">",
"      Yin W. Radiotherapy of carcinoma of oesophagus in China. Chin Med J (Engl) 1997; 110:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/79\">",
"      Sur RK, Singh DP, Sharma SC, et al. Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1992; 22:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/80\">",
"      Calais G, Dorval E, Louisot P, et al. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1997; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/81\">",
"      Iwasa M, Ohmori Y, Iwasa Y, et al. Effect of multidisciplinary treatment with high dose rate intraluminal brachytherapy on survival in patients with unresectable esophageal cancer. Dig Surg 1998; 15:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/82\">",
"      Gaspar LE, Qian C, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. Int J Radiat Oncol Biol Phys 1997; 37:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/25/30106/abstract/83\">",
"      Steyerberg EW, Homs MY, Stokvis A, et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005; 62:333.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2472 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-197.136.42.3-505F0169A0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30106=[""].join("\n");
var outline_f29_25_30106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GRADING OF DYSPHAGIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preoperative EUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluation for distant metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Criteria for unresectability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10737238\">",
"      - Distant metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10737245\">",
"      - Unresectable primary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10737252\">",
"      Thoracic or abdominal esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10737259\">",
"      Cervical esophageal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intraoperative staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SURGICAL PALLIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ENDOSCOPIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXTERNAL BEAM RADIATION THERAPY (EBRT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Palliation of dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications and disadvantages of RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - TE fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMBINED MODALITY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cervical tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Conventional chemoradiotherapy for thoracic and abdominal esophageal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - RTOG 85-01",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Relief of dysphagia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Patients with a malignant fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment intensification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Radiation therapy (RT) dose intensification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Chemotherapy intensification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Induction plus concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Post-chemoradiotherapy surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Salvage esophagectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      BRACHYTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2472|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/36/4678\" title=\"figure 1\">",
"      AJCC diagram of the esophageal anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2472|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/7/28785\" title=\"picture 1\">",
"      Tracheoesophageal fistula Endo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/35/4668\" title=\"table 1\">",
"      T stage esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/28/6603\" title=\"table 2\">",
"      Dysphagia grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13934\" title=\"table 3\">",
"      TNM staging esoph SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/24/4494\" title=\"table 4\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/61/19420\" title=\"table 5A\">",
"      Brachytherapy esophagus CA selection criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/30/23020\" title=\"table 5B\">",
"      Radiation therapy for esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/49/2846\" title=\"table 6\">",
"      Carboplatin and paclitaxel with RT for EGJ cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34282?source=related_link\">",
"      Surgical oncologic principles for management of resectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43378?source=related_link\">",
"      Treatment protocols for esophagogastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_25_30107="Symptoms of acute HIV infection";
var content_f29_25_30107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of common symptoms in acute HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        No. patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        96",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenopathy",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngitis",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rash",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myalgia/arthralgia",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea/vomiting",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropathy",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Niu, MT, Stein, DS, Schnittman, SM, J Infect Dis 1993; 168:1490.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30107=[""].join("\n");
var outline_f29_25_30107=null;
var title_f29_25_30108="Types of vacuum delivery cups";
var content_f29_25_30108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of vacuum delivery suction-cup devices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Name",
"      </td>",
"      <td class=\"subtitle1\">",
"       Size",
"      </td>",
"      <td class=\"subtitle1\">",
"       Material",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Soft cups (silicone or plastic)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gentle Vac Bell",
"      </td>",
"      <td>",
"       60 mm",
"      </td>",
"      <td>",
"       Soft rubber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kiwi ProCup Bell",
"      </td>",
"      <td>",
"       65 mm",
"      </td>",
"      <td>",
"       Soft plastic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mityvac Bell",
"      </td>",
"      <td>",
"       60 mm",
"      </td>",
"      <td>",
"       Soft silicone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Secure Cup Mushroom/Discoid",
"      </td>",
"      <td>",
"       63 mm",
"      </td>",
"      <td>",
"       Rubber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Silc Cup",
"      </td>",
"      <td>",
"       50-60 mm",
"      </td>",
"      <td>",
"       Silicone rubber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Soft Touch Bell",
"      </td>",
"      <td>",
"       60 mm",
"      </td>",
"      <td>",
"       Soft polyethylene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tender Touch Bell",
"      </td>",
"      <td>",
"       60 mm",
"      </td>",
"      <td>",
"       Soft silicone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vac-U-Nate",
"      </td>",
"      <td>",
"       65 mm",
"      </td>",
"      <td>",
"       Soft silicone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Velvet Touch Bell",
"      </td>",
"      <td>",
"       65 mm",
"      </td>",
"      <td>",
"       Soft silicone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Rigid cups for occiput anterior position. All of the following cups are mushroom style.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Flex Cup",
"      </td>",
"      <td>",
"       60 mm",
"      </td>",
"      <td>",
"       Polyurethane",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kiwi OmniCup",
"      </td>",
"      <td>",
"       50 mm",
"      </td>",
"      <td>",
"       Rigid plastic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Malmstr&ouml;m",
"      </td>",
"      <td>",
"       40-60 mm",
"      </td>",
"      <td>",
"       Metal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mityvac \"M\" Style",
"      </td>",
"      <td>",
"       50 mm",
"      </td>",
"      <td>",
"       Rigid polyethylene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Rigid cups for occiput posterior position. All of the following cups are mushroom style.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bird Posterior Cup",
"      </td>",
"      <td>",
"       40-60 mm",
"      </td>",
"      <td>",
"       Metal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kiwi OmniCup",
"      </td>",
"      <td>",
"       50 mm",
"      </td>",
"      <td>",
"       Rigid plastic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mityvac \"M\" Select",
"      </td>",
"      <td>",
"       50 mm",
"      </td>",
"      <td>",
"       Rigid polyethylene",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30108=[""].join("\n");
var outline_f29_25_30108=null;
var title_f29_25_30109="ACST fatal disabling";
var content_f29_25_30109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fatal or disabling stroke or perioperative death in the Asymptomatic Carotid Surgery Trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The risk of fatal or disabling stroke or perioperative death in the Asymptomatic Carotid Surgery Trial (ACST). The net five-year risk for fatal or disabling strokes or perioperative death in the CEA group was reduced by nearly half compared with the CEA deferral group. About one-half of the strokes in the trial were fatal or disabling.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363:1491. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30109=[""].join("\n");
var outline_f29_25_30109=null;
var title_f29_25_30110="Nodular melanoma";
var content_f29_25_30110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular melanomas present a discrete nodule, usually with dark pigmentation, although they may be amelanotic, as depicted above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30110=[""].join("\n");
var outline_f29_25_30110=null;
var title_f29_25_30111="Supracondylar anatomy child";
var content_f29_25_30111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Anatomy of the distal humerus in the child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 383px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF/Ae0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNGaACiijNABRRRmgAooyKM0AFFGaM0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAxmwaTfVa4l2uRUHn89awlVSdjRQbNDfSF6pCfPemtPUOuilTZf8AM96Tf71nfaOetKZ6X1hD9kzQ30bx61m/aKT7R70fWEHsmam8U5WBOKyTdY71NZ3O+dV9a0jVTZDg0adFFFbmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYl9LiZh71T82n6i3+kyfU1UDV4tab5mehTj7pcWXimNIagVjTs1j7Rs05STeaQyHFRMaaTUc7HykvmGmmQ4qPNNY1XOLlCScirWjTFtQiHqT/KsqZqs6G5GpQf72K6aE/eRnUj7rO0ooor2DzwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5O/k/0mTPXNVg1N1STGozj0c/zqFGzXztefvM9WnH3UXUPFSquRVaM8CrsY+Ws6eo5aEDjFRsalm4NVmNTJ2Y46ocWprPxTSaikbApcxViK4fFS6JKP7Vtx/tis+7kwKTQJs63arnrIP511UJe8iKkfdZ6dRRRXvnkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5/qz41S4H+2f502Jsiq2uybdZuR/tn+dFq+7FfMYh++z2qa91GpF0FacC5SsuHqK17b7lPC6szraIqXIwTVNzWheDms6Wor6SKpu6GE1FKflNPNQTHANYXNbGZfPgHmq/h2U/8ACQ2Qz1lX+dJqD8GqfhuU/wDCS2A9Zl/nXTQfvoU17rPbaKKK+nPDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDynW3361cn1kP8AOp7LtVPVG3atcH/bP86u2PQV8nWd5s92C91GrD1FbNt/qxWRD1Fa9sRsrbB/EYV9ivedazpK0rzkms6SoxHxDpbEBqtcfdNWjVaf7tcxujAv+hql4b48U6f/ANd1/nWhfDrWPZyeRrVpIDjbKpz+NdFF2kmEleLR73RRRX1R4IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUE4BPpRTZDiNj7GgDyC9bdqU59XNadgeBWNO26+mP+2f51sad0FfJVd2e+tkbEPatS3+7WZD2rThPyVrhdznrbEVzyaoSVduDzVKSlX3CmQPVef7pqw/Wq83SuY3Rh33eufvDtmVh2NdFfDg1z2oDFaxKPeNLnFzptrMP+WkSt+YqzWD4Fn+0eFrBiclVKH8CRW9X1VOXNBM8Ga5ZNBRRRVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNlOInPsadUF++yxuH9I2P6Um7Ia3PGy265kPqx/nW3p3QVhQglicd63dO6CvkZnvdDZi7VqQD5BWZByRWtEvyVvhFdnNXZWuByapyCrs/WqkgorLUIFWTGarTdDViTrVeXoa5ToRkXo4NYGoL8pro7sdaw71M5FaRKO6+E98JdLubMn54ZN4+jf/XFd3XkXwvuTb+JTAxws8TLj1I5H8jXrtfR4GfNRXloeRi48tR+YUUUV1nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVneIpPL0O9YdfLNaNYnjN9nhy7IOMgD9azrO1OT8i6avNI8ztORW1p44FYtn0rdsB8or5OR7hrW4+YVroMR1lWgJkFbAUiOu3Bx0bOOu9UUJvvGq7jirEv3jULdKipuyo7FKUc1Wk71cmFVHFcjVmdEWZ10ODWNcrW7crwaxrodaqJaKuiTC08R6fMTtUTpuPoCcGvdK+f7pTgMOCDmvb/D1+up6NaXanJeMbvZhwf1zXtZZPSUDz8dHaRo0UUV6p54UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXG/Em9Edjb2in5pX3n6D/65rsq8s8eXZuvEbxDGy3URjHr1P8648fU5KL89DpwsOaovIzbMdBXQWa4UVi2K8iugtV4FfNSPVZqaeuWzWm5xHVKxXAqzO/y4r1MP7lM4avvTKUvU1Cakc81Ga5JvU2S0IZVqrIvWrr8iq7ispI0izOnXKmse6j5Nbsy4zWZeLULQ1Rz12MAiu8+E+orJY3Wnuf3kT+ao9VPB/Ij9a4i/XAzU/gm//s/xPaSMcRyt5T/RuP54rtwlT2dVMyxEOem0e3UUUV9GeKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXCeJfHN9a+LJfDnhjQf7b1O2svt90JLwWyRIThVDFW3O2OBgDHeu7rivE3gP+0/Eba9o+t3+h6rNafYbmW1SNxPDnIBV1IDA9GGCPegDG8O/F7Stb1CydI1tdEn0CXXJLyd8ND5c4heNlAxwd3IPbjrWxD8UfCkmnX95JfXNutk0KzQ3FlNFNmX/AFW2JkDtv/h2g5rJj+Dfh2KFLOKS6TTV0KTQvIDDcUeYStLux9/cM9MZPTtVXT/gvp1ppclqNSMcyTW1za3Vnp1payQSwMWjdjHGPMOTzvyOuACSaAOih+J3haTULXT5Lu9t9RuRlLS4065jlHziP5lMeV+Yjr256c0J8TfDH26/tLi6vLSaytZb1xdWE8IeCIZkkj3IN4A5+XJI6ZpdB8EzWHjBPEup67d6rqQ0+TTmMsMcalGmWQEBAAMbQMfU1x+nfAnTrJ7sjW7uUTWN9YbntoRIVuQQzySBQ0rjP3nJ6Dp3AOotPiz4NubfUJ11V44rG3jupTPaTRFonIVHRWQFwWIUbQckjHUVO/xO8KxaSuoXF9cQRm9GmtDJYzidLkqXETQ7N4YqCRkYNZGr/CLTNVMZudRvFMWi22jxtGFDJ5EwljmBIPzbgOMYxU0XwttvNtrq81a7utTXXIdduLp40UzyRxtGqbVACoFPbmgDotE8Z6Lrfhi71/TJ5p7C0EvngQOJY2iBLoYyN24Y+7jJ4x1ri/Cfxl03UPDFtrPiCBtP+2tK9raWkNzdSiCMAvI4EQwqg8suU9GzkDsvC/hODw/Za9bw3Msy6tqN1qLs6geW05yVHqB2rlv+FSW0GiaHZ6drl/ZXel2Eumfa4442aa3l++rKwIByMgjp70Ab7fEbw22q2+n2t3c3s80UM5ays5riOKObHlNI6KVQNngkjjk4FJp3xH8O6kbxrCTULiC1SVzcRadcNDL5Zw4icJtkIPGFJJ7Zrmrz4K6RPq+iXUWoXMFtpK2yW8ccMImAhACj7QF8zBxkjPUnGM1VHwN01rjW55Nbv0m1O0ktGe0hhtTtdgxZ/LUCRuAMt1BOeTmgDv8Awl4v0jxWL0aRLP59jIIrq3ubaS3lhYjIDI4BGRyDXQVxHw4+H1v4IutZuLe9Ny+pmAuq2sVvHH5SbAFSIBQCPb8zk1qaroeox6hNqfh7U3gu5SDLaXZaW1nwAPu/ejOABuQ49VagDoJXWKJ5G4VAWP0FeKTTve381xJ9+Vy5/E12Wt+Mlg0u4sNZtJdI1iVfKjhmO6KcngmGUfK/Bzjhh3UVx9lHkivHzSesYno4KOjkaunx9K37ZelZlhFgCty1j6V5EVzSOubsi9D8qimTPUh4Wqkhy1ehOXLGxyRV3ca1MNPzxTTXK9TZDcVG61NikYUNBcz514NZd0uRW5NHWZdR9axasbQZzl9HuU1iSoUbjjmuluo+tYt5H1qoss9n8J6iNU8P2dwW3SbAknruHB/x/GtevK/hbq4tdRl06ZsR3PzR56Bx2/Efyr1SvpcLV9rTT6ni4in7ObQUUUV0GIUV53YfFC31TxfeaJpGkXN4tjf/ANnXU4uYEeOQMFZxCziRo1J5cDoGIziukXxl4ea3tZ11a2MN1LLDC2Th3iDGRRx1UK2fpQB0FFcjafEjwfdxXclvr9m8dpbC8lbLACEkDzASPmXJAJGcE4ODTLr4meDrayivH122e0lLhZ4VeVPkIDksgIABI5PFAHY0Vzd9468M2OqWunXGsWwvLlY3jRMv8shxGSVBChiRgkjOaisPiD4Uv21AWeuWkosIJLmcgnAijyHkU4w6gg5K5FAHU0Vx9l8TPBl7balcW3iKweDTolnun3EBEbgMMj5gSQOM8kDqRVPwx8UND17VNQtVkFtFDfRafazSll+1yPF5gCqVBU4yMHrigDvKK4iL4j6PceJLbTrORLiwlsLm/bUEk/doIJAjrjHODnkHsas23xI8I3Fhe3i65bx29k0aXLTq0RiMhwm5XAIDHocYoA66iuP8VfELRNB+H9x4vimGoaYq/uTbtkTtu2hVPT7wPPsetRaJ8SfD97HaQahqVhY6vNEJjYC58xlUozgg4G4bF3ZA4oA7WiuUsfiH4TvrPUbqHW7ZINORZLppw0JiRvusQ4BwTwCOp4rK/wCFu+EG17SNKgvpZptTeSNHELKsToFIWQNhlLbxt+U++Bg0AegUVz6+MvDzW9rOurWxhupZYYWycO8QYyKOOqhWz9KoD4l+DX0038XiGxmtRIsO6FjIS7LuChVBYnGTgDIA5oA6+iuV8R+NtP0z4e3ni/TimqadDbfaY/IkAEy5xw2Dj8uMVAfiBpFrPq/9s3Vnp1rp7WqNNJcbjunjDqHXHydeOTkc8UAdjRXIR/EnwhLov9qxa7bPZfaDaBlDFzMBkoExvLAc4x056V0ej6pZa1pltqOlXUV3Y3Cb4pojlXHtQBcooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqesXyabp091IR+7X5Qe57D86UpKKuxpNuyPP/ijLBql1HpU6Rz20a7pI3XILH/AY/OuNstN1XSPn0mQ6hZj/AJcrmTEij/pnKf8A0F8/7wrT8yW7uZJ52LyyNuYnua3LCL7or5mviHObl0Z7MKShFITw3q9lqjvBCzw3sQBltJ18uaP3Knt/tDIPYmurgQKtYmoaBY6vFGL6E+dEd0NxGxjlhb1Rxyp+h575FUvtWu+HeL5H1zTF/wCXiBALuIf7cYwJB7phv9k9aujTj8SMqknszqpSQKqnk1W07VrLV7MXOnXMdxCSQWQ/dI6qR1BHcHkd6lZwO9KpLWwoLQcxxSBvWq010ijk1Ta/XPBrncrM1UbmvuFH0rLjvlP8VW4bgN3q41O4nCxYZciqdzDkcCryMGFK6Air5VJE35TlbuHBNYt5F1rsL23znisC9gxnisWuV2OiMro5dme2uFliYq6MGVh1BFe3+FdYTW9HhuQR5wG2ZR/C46/414zew4zVzwjrkug6qsmSbaQhZk9R6/UV24PEeynrszHE0fax03R7lRTY3WSNXQhkYAgjoRTq+gPHPLNY+Ex1rxna65qmq2bra6gL+JrfSkgvCFbKQvcq3zRjgcruIHWsuT4O6ha+WbfxIbqwsLm+vbLT2sUVt1xHICjS7+eXyCQB7ens9FAHhWg/BrVNS8FwW/ifWFt9R/4R9dGggjtFK2KllZ9xWQ+c2VAyCoxnjvXUfEj4X3HjIWiR68bS2i06Swa2mtTPESwAEyqJFCyDpk7uOmDzXptFAHmuk/DW+0TUnuNF8RLbw3ltZW2pRS2AlNwLaMRAxtvHlbkGDkPjORzWXY/BloNMlsLjxC9xbQaPeaNpg+xhGto7gEM8hDfvWAwB9wcdM80vx08TazYax4O8P+GL6Sy1PVL4bpIwCVjyE5BBBXLk8j+CvXaAPJtf+DiawIy2ttC8WhWmkRstqDiS3nEyzEF8EEgAoe38VZnjL4Ya43g7xZJa3o1nxPqt/aahayW8S2X2aeLYodS0jYAUE9c44GTzXtlFAHmMPwojtYtKj0zWJ9PFh4fl0RHt4sSBpNpM4fdw24E4x1PUVg2PwMkhtNTjn8QwPJfGxLPFpxQA20u/JBlYsz9yT1yeele2UUAc18SPC/8AwmngnVfD32z7F9uRU+0eV5mzDq2duRn7uOo61TTwUyeIPGmqR6rNDJ4jtILZTBHskszFE6b1fJy3z7hwMFe9djRQB4np/wACRHaapHqHiETTXlpbW4mt7HymWSCUSrM26R/MJIG4Hrz04x1M3gbXrzXvD2uah4pt5tU0i4uGDJpQjikgmjjR4wnmEhv3ZIcs3LHjAAr0OigDx6D4NXcV3ap/wlRfSrK8vLu1tG09dyfaUdWBkD5bBkJBwPTHcaGq/CWO98I+ENKi1fy77w2gSC6a23RzAx7HDxBwcEejgj1r1GigDgp/h6svwlufBK31vAJ4ZIjc29nsjQvIXJWLeeMnpu981m6l8Kftup6tef2zs+36hpl9s+y52fY0Vdmd/O/bnPG3PQ16fRQB5Jrnwaj1LU73Uota8m+l1aTVIC1rvjjEkKxPE6hwXBC53BlIrvvA/h8eF/C9lo6yQSC38wlreDyIyXkZztTc2BlvUnvmt2igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvPPiJqQnvIrCF8pD80gH949B+A/nXa61fppumT3T4yi/KD3bsPzryFC9xcPLISzuxZj6k15mY1+WPs11O3B0rvnfQtWMOSK6fT7fkGsvTockcV01pFtUV41OPNI7qkrIk27VqGRuTUsrYqnM+ATWk5W0RlFXMHWtCtri6a/s5ZdN1TAH2u2wC4HQSKflkHswOOxHWsC58U3ulHyvEUCLGOBqFqCYG/31OWj/AByv+1XRandbVODXM3UxkYg8g9aUZ6WlqaqHVFiTU/PQSRyB0YZVlOQR6g1W+2MW61zsukPaSNNocwtGJ3NbsN0Dnv8AL/Cfdce4NXNOmuLiJjd2jWsyNtK7w6tx1UjqOe4B9qUordMtPozaW7Yd6u2molWAJrEzgUiuQ1RYo72xvQ4HNakUgNcHp92UYDNdRY3BZQacZOLMpwuak0e4VjX9tweK2onyOajuoQy5AraUVNXMotxdjhb+HrWHcR4Y12mo2oyeK5y9t8E8VitDqTudf8NvExJTSL5/+vd2P/jn+H5V6PXzuysjhkJVgcgjtXrPgPxR/a8H2S9ZRfxDg9PNX1+vrXs4HFXXs579DzsXh7fvInX0UUV6ZwBTfMTzTHvXzMbtueceuPSnV5B+0lJqGkeGtK8T6HcSWupaVeBRKn/PKQYZSOhBZY+DxQBk2A/4S39qG8uD89n4asvLUnp5mMY+u6V/++K91r5I+APjHxAPEutQ6P4fj1fVNYnFzd3Us5iSEZYksdpwMux9T0AJr6ztfO+zRfavL8/aPM8vO3d3xnnFA2SUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKz9e0xNZ0e706WWSJLhNhkjOGX6UntoVBJySk7I0KK8t/4U1pv/AEG9X/7+L/hXbeD/AA5D4X0k2Ftc3FyhlaXfOQWyQBjgdOKiEpt+9G3zO3EUMLThejW5n25WvxublFcP4t+HVn4l1htQuNS1C3dkVNkDgLx9RXN6h8P9O8JpFq0WsanJcwSKYY5HUq79s8dO9ROrOF246LzLp4XCTgm6zUmtuV79r3/E1fHmrm8vfsMDZggPzkfxP/8AWrDsoulZ1xZ/2hZywSu6+cMM6nn61nWvw+tZjzqF8Pow/wAK+erVPayc5M9TCYfDqFqlTlt5X/U9H0yHpxW4AFSuc8IaJFoGnG1inmmUuZN0pBPOOP0rO8U+CrTXtUa+mv72FygTZEwC8fUU6doK5j7OjOs4SqWj3t+lzqpn61lX04VTzXK2PgCz02/t7yPUb+R4XEgV2GCR2PFXfEUQvrKe2d2RZF2lkPIrGTuzSdGjCSjTnzLq7Wt8rlXUJyxPNZLsSawJfCVup4vLs/8AAh/hWnpWnrp9sYUkeQFi2X61VkbVqOHhG9OpzPty2/UtCpFBPasjUPD0Wo3ZnkuJ4yQBhCMcU6y8JwWtzFcLd3LNGwYBiMHHrxRoVGjhnDmdXXty/he5rFTTDGQc1NfWYvLSW3ZmRZBgsvUfSsA+DLf/AJ/bv/vof4UlYmhSoTV6tTlfpf8AU3YSQRXQ6Zc4ABNctpWmLplsYUkkkXcWy5yf88VX1Dw7Dqd558t1cxEgLiMgDj8KLJkxp0XUcZTtHvb9D0+CbpWhGwdcGvMdE8F2lrf212l/eu8LiQKzDBweh4ruNRtF1PTLixlkkjSdNheM/MPpVwlZ2MMRQoxmlTnddXa1vl1LF9ADniucv7brxWafhfYFcjVdSP8AwNf8K1dK0CLRdOa0hmmnXeX3SkE844/SiouqNJ08PCP7qrzPtytfqc7cxbSeOKqJJLbXCTW7tHKhyrKcEGn+IvC8WoXzXL3NxGxAXahGOKx4vDEVrcRzLc3DFGDAMRg/pSi1vc3jRwzhd1dbbcv4Xue/eENej13TFkJVbuP5Zox2Pr9DW7XzsWkSKeJZZY450MUvlnBKnqBXVaR8LtE1axS6s9e1do26jzFyp9CMda9rDYuVRctrteZ5SwWG1lVq8n/brf6o9frkvit4buPF3gHVNEsjELm68oRtKcKpWVGySPQA1o+D/DkPhfSTYW1zcXKGVpd85BbJAGOB04rD8W/Dqz8S6w2oXGpahbuyKmyBwF4+ortcpct0tTjp0sO6zhKpaHR8t7/K5o/D3wVpXgXQI9N0mPLHDXFyw+ed/wC83t6DoB+JPT157oPwusdG1i01GLVtTme3feI5XUq314r0KiDk17ysTiqdGnJKjPnXpb9WFFFFWcwUUUUAFFFRLcQs4VZYyxYqAGGSR1H1FAEtFNkdY0LyMqIOSzHAFOByMjpQAUUUUAFFNeREKh3VSxwoJxk+gokdY0LyMqIOSzHAFADqKAcjI6UUAFFFFABRRRQAUUUUAZ9hrOnahqOoWFldxTXmnsqXUSnmFmG5QfqOasaje22m2M97fzx29pAhklmkbaqKOSSewry7RNL8XeH/AImeM72y8Pw3em67c27w3r3yIsISLZuaP7zDJ6DB4rzrQvhD4qa18R217pdvZRal4eltDEk8Ihe+EqPEwWMA4+U4ZyzdcnnFAH03BLHPDHNC6vFIodHU5DAjIIp9fN/iH4V+ItSg0Pbo8kenwaWLQadb38IksbkSszTI7qy/PkHeh3Dp0GK6Of4d67KnjvUHs4brWrxI00r7ZeM8TA2yRy7lBC5JDDLKMnGeKAPW9c13TtCWxbVbjyBe3cVjb/Izb5pDhE+UHGT3OAO5rSr5y8N/DHxTYssf9n/Z7FPEularFbvcW+I4ogfPYLEFQHOOFXJ4+8eT6J8V/C2oa9rPh68j0qHX9GshOLvRprgQrM7qojk+b5W24PDdM5HNAHpNFeBXfw38SzeJYLqDTbe3kMumyWeoDUC7aPBAiia2UH5nB2sMjh92W5qXSfhhrVnreka0lsIdZi8RXlxPdi53MthJ5m0Y3YIyVOwf40AezXWuada69Y6LPcbdTvYpJreHYx3pHjedwGBjcOpHXijXtd07QLWC41a4+zwz3EdrG2xn3SyNtRcKD1Pfp614P4Q+FGsR6rYJr+jwWka6bqFnqmrJerLJeyzY2znnfnHIJ5HtgVT8CeEvEvin4f2mt3ubrVLnV9O2b32AWVkypvAfkFiruf72Qe9AH0tRXhWhfDrxHY/Fd9c1COe5/wCJpNdJqUN5Coa2kyBFIpTzSFUgbAdoxwRXret23iOa7RtD1XSLO22ANHeaZJcuXyckMtxGAMY42noeecAA2qK5X7D44/6GHw3/AOCGf/5Mo+w+OP8AoYfDf/ghn/8AkygDqWIUEsQAOSTXknivVzr2s7YWzZW5Kx46N6t+NQ+OdU8YIzaSmv6FKWH75oNHmjK/7OTdN+Nc7Y6Z4mRRt1bRh9dKlP8A7cV5GPxCl+7i/U9DC0nH32vQ6W2h4FbthAFArmdJsfES3cTXmqaRLbA/OkWmSRuw9mNwwB/A12UC4UV5Ntd7nXKWhYXgUyQ0pOBUTniib6ExRWu3wprnb5sk1r37kZFYVyck1MTVIzpVyaAlTlM0+GMlqsobDEeOKuCHKip4IgB0qwsftU3FczTCRTCh71qtH7VC8XtQFzNlXimRjBq9LFxVYrg0DNGwkIIFbkD5ArnLU4IrcticClsyJI00PFQzx7s06NuKeTkGt1qjHZnP39uMHisK5hwTxXXXiAisO7gznisXozeLujjNRTVRcP8AZILJoONpkldWPHOQFI6+9WPDniDxJoN8Zre30542GJImuJAGH/fHX3rXmixnjiqE0NbQquDTW4pQUlZ7HqWnap4p1GziurS08PPDIMgi+m49j+661Z87xh/z4eH/APwNm/8AjVcD4J19tD1Dyp2JspjiQf3T2YV7ECGAI5B5r38NiFXjfr1PJr0XSlboc353jD/nw8P/APgbN/8AGqPO8Yf8+Hh//wADZv8A41XS0V0mBzXneMP+fDw//wCBs3/xqtHRn1p2l/tq306FQB5f2Sd5CT3zuRcdvWtSigDy/wDaI0251fwJaafZvcxvc6rZxNJbg741aTBbj0BzXm2mwfEPRviL4g1W/hku/Es3g+SaKGIGWBZkuEjRUA+UsVi8zaOcuRX0zRQB82WHjDxz/YU7SazdS2Ul9YpdXcdjJLdabA+8XDfNaRITkIAArlAT14JX4dS6jY+JtHkitbu+tZvEuvTvPdaen2mVPs+5HBaNTEznrt2ZJ2kY4r6SooA+TrnxL4v8Q+GvFum6jLqt7YXPh17oQ3VtmSG5E8a7Nwt4hnaxJRd4H944r2/4k6lrek+CdGk0Nrq3WS6tYdQurW28+a0tCP3kiJtbJGAPunAJOOK9CooA+ePEnizxTb5Gi674iuLJNPeXSLk6MpfU7wTsvkzDyfuhQAMBMg7smrfjHxB4/hvvGF/Z6ld2sehz6UbbTYrKKSKfzkiE6lyhdlBZzw3H4DHvlFAHzjfX2u658SNFTWbrVlvLPxVKiaetjttrW0WNxFMJPL+ZmBzkuQcn5eKoalrvjTxV4K8f6VrMssy+H9Pk026EVtGPt94Z2KyLtXIAiVPlGOWzivp2qGkaPp+jpdLplpFbC6uHu59g/wBZK+Nzt6k4H5UAeH674l8c2nj9bGC7bTdNgeyFlFJbSvFeQlF84fJbSFnJJXPmR7PQ8mvf6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsDxfrq6Lp58oq15L8sSHt/tEegrS1i/j0zTLi8l5Ea5A9T2H515EzT6neyXl4xeWQ59h7D2rhxuK9jHljuzqw1D2j5nshLSB3kaaYlpHO5mPUk1rwR4FRRxEAEdq0baInGa+ebuz1G7Fm0QYFX0XAqKCLaBVkDitqcTCTuxj4qBhxUr0w1FSJcTLvlyKxLhOa6O7TKmsK5XDGs0aJlNVxVmJMVGq81biXgVTGSxDAqdSBTFXFOIpCFcioyKcAc07FAFWUcVSkX5q0JcVVK5NA0NgHIrcsxlRWTGuGFbVmuEpMTLCdKcetC9aU8VrB6GUkV7hcis6ePNaktVJF4qJlQehhXUeMmsq4IUEmtq/wCCap6Fpp1rXIbMkrFy0hHZR1/w/Gqpxc2ordluSirs3PAfhkX7LqV+n+jKf3UZ/wCWhHc+38667VvFNlp9wYArzyrwwjxhT6ZpnifUf7I0+G0sQElkXYmP4FHGa5nT9MBTdINzNySa9SpV+qr2VL4urOGMPbv2lTbodfoniKy1ZzFCXjnAz5cgwSPUetbNeY6hZPaOtxalo5YzkMvBFdx4Y1T+1tLSZ8CdDslA/vDv+NdODxbq+5PcxxFBQXNHY1qKKK7zlCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOU+JbEeHFG7AadAR69TiuMslBRcDtXc/EO1Nz4ZmYdYXWX9cH9DXD6YcxrXg5mn7X5Hq4N/u/macUXArQt0xVaHoKtRGvNW5uy2nSn5qIMKeG4rqizFojfrTWoc800molqaIY65FULm1D8gc1oZoKhqw2KMM2hB6U4Rle1azRn0qNoweopjuUBmg1cMI7VE0RzQFyCkZjipjERUTjBwBzSGVzk9aY2B0qdwR2oigZzk0wGW0ZZwa3YUIQcVBbW20DIrQQDFCV2TJkQU5oYHNWQBTWAreMLIycirKvFVZBjNW5WzVSc4Wsqm5pAwdUcLurqfhlp6x2M+oSL+8nbYpP8AcH/1/wCVcXrMucivSYGGk+CoivDJbDH+8w/xNd2XxSk6kvsoxxbfKoLqc5f3H9qa5NODmJDsj/3R/nNb+nxgIMiud0aMJECe9dJbnagrGnLnm5y6jqLliooq6rEGRuOKpeA5/K1e9tM/K6CQD3Bx/WofEGp6hBcNFa6Lc3cWAfOjmiUZ9MMwP6Vg+F9V1WPxMZI/Dd7IxiYbBcwA9vV8VtQTWIi0RLWk0z16iua/t3W/+hR1D/wLtv8A45R/but/9CjqH/gXbf8AxyvfPMOloqppVzcXdoJbyxlsZSSPJldHIHrlCR+teDeMfi74n0LxZ420m2tIrhIcQaPIIciKZYkkk8wjqPLd3Gf+eRFAH0JRXhln8br2HR9FT/hH7nWtTfSrbUb82odSPN7RIsbBjwThig7ZJ4q34o+JusXWuWFt4cs/sukweKbPRLu/lkUyTMxUyxCFkO1cMBv3A+goA9oorxdPi1cad4Qs79LN9Xvbi6vkEFxPsnKQSFTtWCBtwA77QAPvN3O18NfHF54v8Z6oQ7x6O2kaff21q6JmFpg5fLAZPQdTjjjFAHp1FeXf8LZM3juTQbHw7e3VjDqa6VPfR7yYpSBlygjK+WCwBYuD324rFT4zXF94bivpdDm02DVNF1DUNPuYbtJpA9qhLgo0e1T0Kk7gT1FAHtdFeaaL8QdS1S8t9O0PQ21SW106yvNRuLm9S3ZPtCblCgJtdsAk/cXtx0qhpXxjW8igu59Bkg03ULK+vtLmF0He4W15cSJt/dEjkct+dAHrVFeMn43tZ2E93rPhiezjbRIdbshHepMbmOWWOJFbCjYd8qcnPGT2xUdl8Ttc0fxB4sfxdYxxafYajplo8ENwjppsdxEN0pl8tTIu8qTnpuwOByAe1UV4xH8Vbq61nQNWMU9l4auNM1TUJLbaskk8VsRslBKgqSAxCg9xnNdJ8MviLceNLyaG48PXWmRfZUvLe4LO8UqMfulmjQBxkHA3DB4Y0Aeh0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFbUrdbvT7m3cZWSNkx9RXkekvgbTwRxivZa8p8XWn9l+JZWVdsFx+9THTJ6/rn868vM6V4qa6Hdgp2biaMByBVlKy7S4DKCDV1JRXhbHoNFvcRS+ZxVfzQR1pN4qlKxPKWQ1Baq3mAd6ie6C96Oa4WL1Kp5rNN8o7im/2gn96kFjcTDU2SNayU1FR0anm+3fxVpzK2qJ5WaAiQ0GBaoLdn1qQXnvSvEOWRZMAPSmG0XPaoxdj1pDdj1ougsxZLVaWOJVqM3QPegTL2NS3cpJloVIGwKqCYetBm96SdhNXLqtmo5Xx3qqJ8ConlJOSav2mguUmd+OapTvwaHl96rSvkH0qG7miRh3qGa8jjHV3C/ma9J8cERaFFEvAMqrgegB/wriNCs31PxLbRxrmOJxLI3YAHP/1q7rxzA0uib1BPkyBzj05H9a9TDQf1epJdTlryXtYI5/TxiFa2IpPkHNYenSq0IwRkVd8wjoa8+E+U2nG7Jr2UbDzVPwSpl8Rzv2SE/qRVXU7tY4yAeTXR+BtNktLKW5uEKzXBBAI5Cjp+ddWCi6ldPsZV2oUmu501FFFfRHlBWQvhvSEOslbJAdZ/4/8A5m/f/Js554+XjjFa9FAHIXnw28I3kFjFPosBWytxaQFHdGWEdIyysCy+zEipLn4eeFLnXE1ibRoDqKTxXSyq7qBLHjY+0ELuGBzjnHNdXRQByN38NvCN3Z21rcaJA0Ns80kQ3uCplOZOQ2SGJ5BOPatLw/4U0Tw9M02jWCWsjW8VoWVmP7qIEIvJPTJ963KKAOaufA3hq58QjXJdJh/tTzUmMyMyb5E+47KCFZhgYJBPArA8DfCPw34X8O/2dNapqNzJZyWFxeShlaWGQtuQDcdgIbB24zivRKKAOWvfh/4WvbixnudHgaayijghcMyny48bEYgjeowMBs0tp8P/AArZ3N9cWui2sUt7FJDMV3Y2Sf6xVGcIG6nbjNdRRQBzM3gTwzPDHDPpEEkSaaNHVHLMBaAqRFgnoCqnPXIHNZGsfC/Q5vCOv6HocS6UdaSOO5uMNOzBMYOHbk7cgHPU55xXe0UAYNt4Q0KAaVt0+Jzplm1hal8kJAyhWQjoQQozkVH4a8F+HvDNzJPoWmpZyOnlnbI7BUznaoJIUZA4GBxXRUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVg+MdF/tnSysIX7XEd0RP6j8f8K3qKicFUi4y2ZUZODUkeIxTTWcrQ3CPHIpwVYYIrSivkIzmvVLqytbvH2q3hmx08xA2PzrMu/D2h+W3n2dvEp6sDsx+INeRPK5fZkehHGxe6OEF6h/ipDeKBndXTHwt4dbJW8ZR6LcrxSJ4O0RwSt7OwHXEy/4Vh/Z1TuvvNPrUPM4+fVFBwpzVRr2WZwsSszHoFGSa73+wPCtkA07xOR/z0nzn8Aamj8R6FYfJYwEgcfuYQo/XFUsFGH8SaQfWeb4ItnBpp2rT4KWN0QeP9WatR+HNdkJAsXX/AHmA/rXWz+M/+fewcj1d8fyFVG8Xaizfu7SBV9Dkn+dHs8JHebYc9d7RRhDwvrwP/Hp/5EX/ABpk+j65aj59PmYf7GH/AJV0I8U6p/z7235N/jSHxZqikE21sR3wG/xpOODe0mCliOyOUa7mtztuYZImHZ1Ip66iMZzXcWXiyyu2EOpW/kMT1Yb0/wDrVuyaZp9wql7O2kXGQfLU8VcMBCqr053IlinDScbHln9pIBUb6mMZFepf2DpX/QPtv+/YqP8A4RzSM5/s+D8qr+yp90L67DseWHUWbpkUwX7g/eNesjQNKByNPt/++Kjn8N6ROhV7CEe6jaf0p/2XPug+uw7HmMepsCMnNXY9RRgMmuwk8D6OxO1J0z/dk6fnVaTwBp5/1dzdL9Sp/pWTy2r5FrGU2c8LtD0agzqf4hXQDwFaDpe3P5L/AIVEPAMefm1KYj0EY/xqP7Nrdh/WqXc5yW7jXqwzUdpDe6xP5GnQlv7znhV+prtrTwRpMDq8vn3BHaR+D+AxXSW8EVvEscEaRxr0VBgCuijlbveozOpjYpe4jM8NaLHoth5QIed/mlk/vH29hWrKiSxtHIoZGBVgehFOor2IwjCPKtjz5ScnzPc4W98I3lvcM+lzI8JOQkhwy+2e9Imga252t5CD1L/4V3dFccsuoyd7HQsXUSsc7pHhiC1kE964uZxyAR8i/h3roqKK6qVKFJcsFYwnOU3eTCiiitCAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5bxjr8unlbOwI+1OuWfrsH+NcWljc3beZcySSOe7sSf1q3dyfavEWoSScnzig+g4H8q2IFG0AV8zi8RKrUa6HsUaapwXcwv7IYDgGnpo8h9a6aOMVaihB7VnCm5FSq2OZi0MdWFXYtLjT+GugEHtTXi21v9XsZe2bMf7Eg42il+yqOiitFlxTDiodND52Zzw47VC0Y6EVoS4xVOTrXPOKRrGVzNvrVGQkAV0XgK/MtrLYytloOUz/dPb8D/ADrInA8s5pnghyviVlHRomB/Q104Co41lbqRiIqVN+R6LRRRX0p44UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBfXtrp9q9zf3MFrbp96WaQIi/UngUtld219ax3NlcQ3NvIMpLC4dGHsRwa8x+NWjXt7rfgzVG0WfxBoGl3c8mo6XAiyPIXj2xSCNiA+xsnHv9a434hL4huNJsY/A/hnxF4bsjZ3c8MdkskTC43ZVXgglVULY3BnLD5j8hORQB9DVTtdTsLszC1vrWcwTm1lEcqt5cwAJjbB4cAj5TzzXznqepeNNU13XNNsLjxK3iK3tdFks47WRkt7ad4t05uBkKFOGyGBBweMgVo+LvD/AIk1K3mur628QSxWPjtrqNLMsJRYeUoEsSjk4b7pHTLe9AH0M7KiszsFVRkknAArPsNd0jUZoItP1SwupZ4PtUSQXCO0kO7b5igHlN3G4cZ4rw5rTx83xDu3vrjxClt/aDi3jihea0msGXCI2JRErAHJJTfuHU9KzfDXhfxbZaZYtp+nahZ6lD4CuLKKTaY2ju/tIdY9xxh8DIFAH0pRXzxrWo/EDV9N1qbTLDxVpzDSNNit0lQpIbgXS+e6AE87N2c84ByMVcsdF8a6Z4nt5YdR8VXVna+K0tkS5uHljfTnhJkkcEfOofADHhe2KAPe6Kq6nFeTWbpp11Fa3JI2yyQ+ao55+XcuePesT+zfFP8A0Men/wDgqP8A8eoA6Wiua/s3xT/0Men/APgqP/x6j+zfFP8A0Men/wDgqP8A8eoA4+7Q2/iLUEbr57H8Ccj+dblu2VBrm/Gek+ILXV4p5dasnM6csunFRkcdPMPbFWfD8epxyFr/AFG3uYdmAkdr5RDZHOd59+Md6+XxVP2dSWp7NOXPBOx1MZq1E+Kz4nqdZMU6dSxEomir012qqJfekebHeuh1lYyUB8pqtIaGlBqrNOq5ya551EaxgLLJVZmqvNeKves641EAfKa5pNyZvGNi7e3CohyRWj8PLQyXN1fupCgeUh9SeT/SsfQ9Gu9duQzh4rMctKR19l9TXpVnaw2VslvbIEiQYAFepl+FlzKrLZHJiqyUeRbk9FFFe4eaFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEEVnbQ3U9zFbwx3NwFE0qoA8m0ELuPU4BOM9M1PRRQAUUUUAFFFFABRRRQAUUUUAYni7SzqWlMIhmeH95H7+o/Ef0rgtKuwMK3WvWK8/wDFvhqaC4e+0uNpI3O6SJRyh9QPSvKzHCuf7yK9TuwlZR9yRIkgPINSiWuWg1B1+V8gjirP9oN614lmj0OU3zN71G9wAOTWC+oHH3qrPeSynbErOx6BRmmk2HKbVzqCoMBqybjUC5wCSTV3T/DGrahIpmjNvEerycHH0612Wi+FbDTcO6/aJwc75B0PsK7KOBqVN1ZeZhUxFOn5s4+w8O6rqJBMX2eI/wAcvH6da6rS/B1haskl0WupR/f4TP0/xrpqK9elgaVPW135nDUxVSemwiqqKFQBVHAAGAKWiiuw5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK1zp9ncnNxawSn1eME1TPh7SSf8Ajwh/KtWiodOD3SKU5LZmamg6UpBFhb5HqmauQWtvB/qIIo/9xAKmopqEY7IHKT3YUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_25_30111=[""].join("\n");
var outline_f29_25_30111=null;
